1
|
Loibl S, André F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, Cardoso MJ, Carey LA, Dawood S, Del Mastro L, Denkert C, Fallenberg EM, Francis PA, Gamal-Eldin H, Gelmon K, Geyer CE, Gnant M, Guarneri V, Gupta S, Kim SB, Krug D, Martin M, Meattini I, Morrow M, Janni W, Paluch-Shimon S, Partridge A, Poortmans P, Pusztai L, Regan MM, Sparano J, Spanic T, Swain S, Tjulandin S, Toi M, Trapani D, Tutt A, Xu B, Curigliano G, Harbeck N. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2024; 35:159-182. [PMID: 38101773 DOI: 10.1016/j.annonc.2023.11.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2023] [Revised: 11/21/2023] [Accepted: 11/28/2023] [Indexed: 12/17/2023] Open
Affiliation(s)
- S Loibl
- GBG Forschungs GmbH, Neu-Isenburg; Centre for Haematology and Oncology, Bethanien, Frankfurt, Germany
| | - F André
- Breast Cancer Unit, Medical Oncology Department, Gustave Roussy, Cancer Campus, Villejuif
| | - T Bachelot
- Department of Medical Oncology, Centre Léon Bérard, Lyon, France
| | - C H Barrios
- Oncology Department, Latin American Cooperative Oncology Group and Oncoclínicas, Porto Alegre, Brazil
| | - J Bergh
- Department of Oncology-Pathology, Bioclinicum, Karolinska Institutet and Breast Cancer Centre, Karolinska Comprehensive Cancer Centre and University Hospital, Stockholm, Sweden
| | - H J Burstein
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
| | - M J Cardoso
- Breast Unit, Champalimaud Foundation, Champalimaud Cancer Centre, Lisbon; Faculty of Medicine, Lisbon University, Lisbon, Portugal
| | - L A Carey
- Division of Medical Oncology, The University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, USA
| | - S Dawood
- Department of Oncology, Mediclinic City Hospital, Dubai, UAE
| | - L Del Mastro
- Medical Oncology Clinic, IRCCS Ospedale Policlinico San Martino, Genoa; Department of Internal Medicine and Medical Specialities, School of Medicine, University of Genoa, Genoa, Italy
| | - C Denkert
- Institute of Pathology, Philipps-University Marburg and University Hospital Giessen and Marburg, Marburg
| | - E M Fallenberg
- Department of Diagnostic and Interventional Radiology, School of Medicine & Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany
| | - P A Francis
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - H Gamal-Eldin
- Department of Surgical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt
| | - K Gelmon
- Department of Medical Oncology, British Columbia Cancer, Vancouver, Canada
| | - C E Geyer
- Department of Internal Medicine, Hillman Cancer Center, University of Pittsburgh, Pittsburgh, USA
| | - M Gnant
- Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria
| | - V Guarneri
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova; Oncology 2 Unit, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy
| | - S Gupta
- Department of Medical Oncology, Tata Memorial Centre, Mumbai, India
| | - S B Kim
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - D Krug
- Department of Radiation Oncology, University Hospital Schleswig-Holstein, Kiel, Germany
| | - M Martin
- Hospital General Universitario Gregorio Maranon, Universidad Complutense, GEICAM, Madrid, Spain
| | - I Meattini
- Department of Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, Florence; Department of Experimental and Clinical Biomedical Sciences 'M. Serio', University of Florence, Florence, Italy
| | - M Morrow
- Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA
| | - W Janni
- Department of Obstetrics and Gynaecology, University of Ulm, Ulm, Germany
| | - S Paluch-Shimon
- Sharett Institute of Oncology Department, Hadassah University Hospital & Faculty of Medicine Hebrew University, Jerusalem, Israel
| | - A Partridge
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
| | - P Poortmans
- Department of Radiation Oncology, Iridium Netwerk, Antwerp; Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
| | - L Pusztai
- Yale Cancer Center, Yale School of Medicine, New Haven
| | - M M Regan
- Division of Biostatistics, Dana-Farber Cancer Institute, Harvard Medical School, Boston
| | - J Sparano
- Department of Medicine, Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA
| | - T Spanic
- Europa Donna Slovenia, Ljubljana, Slovenia
| | - S Swain
- Medicine Department, Georgetown University Medical Centre and MedStar Health, Washington, USA
| | - S Tjulandin
- N.N. Blokhin National Medical Research Centre of Oncology, Moscow, Russia
| | - M Toi
- Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Bunkyo-ku, Japan
| | - D Trapani
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
| | - A Tutt
- Breast Cancer Research Division, The Institute of Cancer Research, London; Comprehensive Cancer Centre, Division of Cancer Studies, Kings College London, London, UK
| | - B Xu
- Department of Medical Oncology, National Cancer Centre/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - G Curigliano
- Early Drug Development for Innovative Therapies Division, Istituto Europeo di Oncologia, IRCCS, Milan; Department of Oncology and Hemato-Oncology, University of Milano, Milan, Italy
| | - N Harbeck
- Breast Centre, Department of Obstetrics & Gynaecology and Comprehensive Cancer Centre Munich, LMU University Hospital, Munich, Germany
| |
Collapse
|
2
|
Pleasance E, Bohm A, Williamson LM, Nelson JMT, Shen Y, Bonakdar M, Titmuss E, Csizmok V, Wee K, Hosseinzadeh S, Grisdale CJ, Reisle C, Taylor GA, Lewis E, Jones MR, Bleile D, Sadeghi S, Zhang W, Davies A, Pellegrini B, Wong T, Bowlby R, Chan SK, Mungall KL, Chuah E, Mungall AJ, Moore RA, Zhao Y, Deol B, Fisic A, Fok A, Regier DA, Weymann D, Schaeffer DF, Young S, Yip S, Schrader K, Levasseur N, Taylor SK, Feng X, Tinker A, Savage KJ, Chia S, Gelmon K, Sun S, Lim H, Renouf DJ, Jones SJM, Marra MA, Laskin J. Whole genome and transcriptome analysis enhances precision cancer treatment options. Ann Oncol 2022; 33:939-949. [PMID: 35691590 DOI: 10.1016/j.annonc.2022.05.522] [Citation(s) in RCA: 24] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2021] [Revised: 05/03/2022] [Accepted: 05/31/2022] [Indexed: 11/20/2022] Open
Abstract
BACKGROUND Recent advances are enabling delivery of precision genomic medicine to cancer clinics. While the majority of approaches profile panels of selected genes or hotspot regions, comprehensive data provided by whole genome and transcriptome sequencing and analysis (WGTA) presents an opportunity to align a much larger proportion of patients to therapies. PATIENTS AND METHODS Samples from 570 patients with advanced or metastatic cancer of diverse types enrolled in the Personalized OncoGenomics (POG) program underwent WGTA. DNA-based data, including mutations, copy number, and mutation signatures, were combined with RNA-based data, including gene expression and fusions, to generate comprehensive WGTA profiles. A multidisciplinary molecular tumour board used WGTA profiles to identify and prioritize clinically actionable alterations and inform therapy. Patient responses to WGTA-informed therapies were collected. RESULTS Clinically actionable targets were identified for 83% of patients, 37% of whom received WGTA-informed treatments. RNA expression data were particularly informative, contributing to 67% of WGTA-informed treatments; 25% of treatments were informed by RNA expression alone. Of a total 248 WGTA-informed treatments, 46% resulted in clinical benefit. RNA expression data were comparable to DNA-based mutation and copy number data in aligning to clinically beneficial treatments. Genome signatures also guided therapeutics including platinum, PARP inhibitors, and immunotherapies. Patients accessed WGTA-informed treatments through clinical trials (19%), off-label use (35%), and as standard therapies (46%) including those which would not otherwise have been the next choice of therapy, demonstrating the utility of genomic information to direct use of chemotherapies as well as targeted therapies. CONCLUSIONS Integrating RNA expression and genome data illuminated treatment options that resulted in 46% of treated patients experiencing positive clinical benefit, supporting the use of comprehensive WGTA profiling in clinical cancer care. CLINICAL TRIAL NUMBER NCT02155621.
Collapse
Affiliation(s)
- E Pleasance
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver
| | - A Bohm
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver; Department of Medicine, University of British Columbia, Vancouver
| | - L M Williamson
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver
| | - J M T Nelson
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver
| | - Y Shen
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver
| | - M Bonakdar
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver
| | - E Titmuss
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver
| | - V Csizmok
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver
| | - K Wee
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver
| | - S Hosseinzadeh
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver; Department of Medicine, University of British Columbia, Vancouver
| | - C J Grisdale
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver
| | - C Reisle
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver
| | - G A Taylor
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver
| | - E Lewis
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver
| | - M R Jones
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver
| | - D Bleile
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver
| | - S Sadeghi
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver
| | - W Zhang
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver
| | - A Davies
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver
| | - B Pellegrini
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver
| | - T Wong
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver
| | - R Bowlby
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver
| | - S K Chan
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver
| | - K L Mungall
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver
| | - E Chuah
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver
| | - A J Mungall
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver
| | - R A Moore
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver
| | - Y Zhao
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver
| | - B Deol
- Department of Medical Oncology, BC Cancer, Vancouver
| | - A Fisic
- Department of Medical Oncology, BC Cancer, Vancouver
| | - A Fok
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver
| | - D A Regier
- Canadian Centre for Applied Research in Cancer Control, Cancer Control Research, BC Cancer, Vancouver
| | - D Weymann
- Canadian Centre for Applied Research in Cancer Control, Cancer Control Research, BC Cancer, Vancouver
| | - D F Schaeffer
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver; Pancreas Centre BC, Vancouver
| | - S Young
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver
| | - S Yip
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver
| | - K Schrader
- Hereditary Cancer Program, BC Cancer, Vancouver; Department of Medical Genetics, University of British Columbia, Vancouver
| | - N Levasseur
- Department of Medical Oncology, BC Cancer, Vancouver
| | - S K Taylor
- Department of Medical Oncology, BC Cancer, Kelowna
| | - X Feng
- Department of Medical Oncology, BC Cancer, Victoria
| | - A Tinker
- Department of Medical Oncology, BC Cancer, Vancouver
| | - K J Savage
- Department of Medical Oncology, BC Cancer, Vancouver
| | - S Chia
- Department of Medical Oncology, BC Cancer, Vancouver
| | - K Gelmon
- Department of Medical Oncology, BC Cancer, Vancouver
| | - S Sun
- Department of Medical Oncology, BC Cancer, Vancouver
| | - H Lim
- Department of Medical Oncology, BC Cancer, Vancouver
| | - D J Renouf
- Department of Medical Oncology, BC Cancer, Vancouver; Pancreas Centre BC, Vancouver
| | - S J M Jones
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver; Department of Medical Genetics, University of British Columbia, Vancouver; Department of Molecular Biology and Biochemistry, Simon Fraser University, Vancouver, Canada
| | - M A Marra
- Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver; Department of Medical Genetics, University of British Columbia, Vancouver
| | - J Laskin
- Department of Medical Oncology, BC Cancer, Vancouver.
| |
Collapse
|
3
|
Greil R, Lin NU, Murthy RK, Abramson V, Anders C, Bachelot T, Bedard PL, Borges V, Cameron D, Carey L, Chien AJ, Curigliano G, DiGiovanna MP, Gelmon K, Hortobagyi G, Hurvitz S, Krop I, Loi S, Loibl S, Mueller V, Oliveira M, Paplomata E, Pegram M, Slamon D, Zelnak A, Ramos J, Feng W, Winer E. Aktualisierte Ergebnisse von Tucatinib versus Placebo in Kombination
mit Trastuzumab und Capecitabin bei Patienten mit vorbehandeltem, metastasierten
HER2-positiven Brustkrebs mit ZNS-Metastasen (HER2CLIMB). Geburtshilfe Frauenheilkd 2022. [DOI: 10.1055/s-0042-1746156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Affiliation(s)
- R Greil
- Dritte medizinische Abteilung, Paracelsus Medizinische
Universität Salzburg, Salzburger Krebsforschungsinstitut –
Zentrum für Klinische Krebs- und Immunologiestudien und Cancer Cluster
Salzburg, Salzburg. Österreich
| | - N U Lin
- Dana-Farber Cancer Institute, Boston, Massachusetts, USA
| | - R K Murthy
- MD Anderson Cancer Center, Houston, Texas, USA
| | - V Abramson
- Vanderbilt University Medical Center, Nashville, Tennessee,
USA
| | - C Anders
- Duke Cancer Institute, Durham, North Carolina, USA
| | | | - P L Bedard
- University Health Network, Princess Margaret Cancer Centre, Toronto,
Ontario, Kanada
| | - V Borges
- University of Colorado Cancer Center, Aurora, Colorado,
USA
| | - D Cameron
- Edinburgh Cancer Research Centre, Edinburgh, Vereinigtes
Königreich
| | - L Carey
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North
Carolina, USA
| | - A J Chien
- University of California at San Francisco, San Francisco, Kalifornien,
USA
| | - G Curigliano
- Istituto Europeo di Oncologia, IRCCS, University of Milano, Mailand,
Italien
| | | | - K Gelmon
- British Columbia Cancer – Vancouver Centre, British Columbia,
Kanada
| | | | - S Hurvitz
- UCLA Medical Center/Jonsson Comprehensive Cancer Center, Los
Angeles, Kalifornien, USA
| | - I Krop
- Dana-Farber Cancer Institute, Boston, Massachusetts, USA
| | - S Loi
- Peter MacCallum Cancer Centre, Melbourne, Australien
| | - S Loibl
- Deutsche Brust-Gruppe, Neu-Isenburg. Deutschland
| | - V Mueller
- Universitätsklinikum Hamburg-Eppendorf, Hamburg,
Deutschland
| | - M Oliveira
- Hospital Universitario Vall D‘Hebron, Barcelona,
Spanien
| | - E Paplomata
- Carbone Cancer Center University of Wisconsin, Madison, Wisconsin,
USA
| | - M Pegram
- Stanford Comprehensive Cancer Institute Palo Alto, Kalifornien,
USA
| | - D Slamon
- UCLA Medical Center/Jonsson Comprehensive Cancer Center, Los
Angeles, Kalifornien, USA
| | - A Zelnak
- Northside Hospital, Sandy Springs, Georgia, USA
| | - J Ramos
- Seagen Inc., Bothell, Washington, USA
| | - W Feng
- Seagen Inc., Bothell, Washington, USA
| | - E. Winer
- Dana-Farber Cancer Institute, Boston, Massachusetts, USA
| |
Collapse
|
4
|
Sit D, Lalani N, Chan E, Tran E, Gondara L, Lohrisch C, Chia S, Gelmon K, Nichol A. Regional Nodal Irradiation for Low-Risk, Node-Positive Breast Cancer. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.745] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
5
|
Galactionova K, Loibl S, Salari P, Marmé F, Martin M, Untch M, Bonnefoi H, Kim SB, Bear H, McCarthy N, Gelmon K, García-Saenz J, Kelly C, Reimer T, Toi M, Rugo H, Gnant M, Makris A, Burchardi N, Schwenkglenks M. 132P Health economic properties of palbociclib in breast cancer patients with high risk of relapse following neoadjuvant therapy: Results from the Penelope-B trial. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
6
|
Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, Barrios CH, Bergh J, Bhattacharyya GS, Biganzoli L, Boyle F, Cardoso MJ, Carey LA, Cortés J, El Saghir NS, Elzayat M, Eniu A, Fallowfield L, Francis PA, Gelmon K, Gligorov J, Haidinger R, Harbeck N, Hu X, Kaufman B, Kaur R, Kiely BE, Kim SB, Lin NU, Mertz SA, Neciosup S, Offersen BV, Ohno S, Pagani O, Prat A, Penault-Llorca F, Rugo HS, Sledge GW, Thomssen C, Vorobiof DA, Wiseman T, Xu B, Norton L, Costa A, Winer EP. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 2020; 31:1623-1649. [PMID: 32979513 PMCID: PMC7510449 DOI: 10.1016/j.annonc.2020.09.010] [Citation(s) in RCA: 669] [Impact Index Per Article: 167.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2020] [Revised: 09/15/2020] [Accepted: 09/16/2020] [Indexed: 01/09/2023] Open
Affiliation(s)
- F Cardoso
- Breast Unit, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal.
| | - S Paluch-Shimon
- Sharett Division of Oncology, Hadassah University Hospital, Jerusalem, Israel
| | - E Senkus
- Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
| | - G Curigliano
- Department of Oncology and Hemato-Oncology, European Institute of Oncology, IRCCS, Division of Early Drug Development, University of Milan, Milan, Italy
| | - M S Aapro
- Breast Center, Clinique de Genolier, Genolier, Switzerland
| | - F André
- Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
| | - C H Barrios
- Latin American Cooperative Oncology Group (LACOG), Grupo Oncoclínicas, Porto Alegre, Brazil
| | - J Bergh
- Department of Oncology-Pathology, Karolinska Institute & University Hospital, Stockholm, Sweden
| | - G S Bhattacharyya
- Department of Medical Oncology, Salt Lake City Medical Centre, Kolkata, India
| | - L Biganzoli
- Department of Medical Oncology, Nuovo Ospedale di Prato - Istituto Toscano Tumori, Prato, Italy
| | - F Boyle
- The Pam McLean Centre, Royal North Shore Hospital, St Leonards, Australia
| | - M-J Cardoso
- Breast Unit, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal; Nova Medical School, Lisbon, Portugal
| | - L A Carey
- Department of Hematology and Oncology, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, USA
| | - J Cortés
- IOB Institute of Oncology, Quiron Group, Madrid & Barcelona, Spain; Department of Oncology, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - N S El Saghir
- Division of Hematology Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
| | - M Elzayat
- Europa Donna, The European Breast Cancer Coalition, Milan, Italy
| | - A Eniu
- Interdisciplinary Oncology Service (SIC), Riviera-Chablais Hospital, Rennaz, Switzerland
| | - L Fallowfield
- SHORE-C, Brighton & Sussex Medical School, University of Sussex, Brighton, UK
| | - P A Francis
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - K Gelmon
- Medical Oncology Department, BC Cancer Agency, Vancouver, Canada
| | - J Gligorov
- Breast Cancer Expert Center, University Cancer Institute APHP, Sorbonne University, Paris, France
| | - R Haidinger
- Brustkrebs Deutschland e.V., Munich, Germany
| | - N Harbeck
- Breast Centre, Department of Obstetrics and Gynaecology, University of Munich (LMU), Munich, Germany
| | - X Hu
- Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
| | - B Kaufman
- Department of Oncology, Sheba Medical Center, Ramat Gan, Israel
| | - R Kaur
- Breast Cancer Welfare Association Malaysia, Petaling Jaya, Malaysia
| | - B E Kiely
- NHMRC Clinical Trials Centre, Sydney Medical School, Sydney, Australia
| | - S-B Kim
- Department of Oncology, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea
| | - N U Lin
- Susan Smith Center for Women's Cancers - Breast Oncology Center, Dana-Farber Cancer Institute, Boston, USA
| | - S A Mertz
- Metastatic Breast Cancer Network, Inverness, USA
| | - S Neciosup
- Department of Medical Oncology, National Institute of Neoplastic Diseases, Lima, Peru
| | - B V Offersen
- Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
| | - S Ohno
- Breast Oncology Centre, Cancer Institute Hospital, Tokyo, Japan
| | - O Pagani
- Medical School, Geneva University Hospital, Geneva, Switzerland
| | - A Prat
- Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona; Department of Medicine, University of Barcelona, Barcelona
| | - F Penault-Llorca
- Department of Biopathology, Centre Jean Perrin, Clermont-Ferrand, France; University Clermont Auvergne/INSERM U1240, Clermont-Ferrand, France
| | - H S Rugo
- Breast Oncology Clinical Trials Education, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA
| | - G W Sledge
- Division of Oncology, Stanford School of Medicine, Stanford, USA
| | - C Thomssen
- Department of Gynaecology, Martin Luther University Halle-Wittenburg, Halle, Germany
| | - D A Vorobiof
- Oncology Research Unit, Belong.Life, Tel Aviv, Israel
| | - T Wiseman
- Department of Applied Health Research in Cancer Care, The Royal Marsden Hospital NHS Foundation Trust, London, UK
| | - B Xu
- Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
| | - L Norton
- Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - A Costa
- European School of Oncology, Milan, Italy; European School of Oncology, Bellinzona, Switzerland
| | - E P Winer
- Susan Smith Center for Women's Cancers - Breast Oncology Center, Dana-Farber Cancer Institute, Boston, USA
| |
Collapse
|
7
|
Nehra J, Bradbury PA, Ellis PM, Laskin J, Kollmannsberger C, Hao D, Juergens RA, Goss G, Wheatley-Price P, Hotte SJ, Gelmon K, Tinker AV, Brown-Walker P, Gauthier I, Tu D, Song X, Khan A, Seymour L, Smoragiewicz M. A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies. Invest New Drugs 2020; 38:1442-1447. [PMID: 32020438 DOI: 10.1007/s10637-020-00904-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2019] [Accepted: 01/27/2020] [Indexed: 11/25/2022]
Abstract
Background The IND.226 study was a phase Ib study to determine the recommended phase II dose of durvalumab + tremelimumab in combination with standard platinum-doublet chemotherapy. Sequential administration of multiple agents increases total chair time adding costs overall and inconvenience for patients. This cohort of the IND.226 study evaluated the safety and tolerability of durvalumab + tremelimumab given either sequentially (SEQ) or concurrently (CON). Methods Patients with advanced solid tumours were enrolled and randomised to either SEQ tremelimumab 75 mg IV over 1 h followed by durvalumab 1500 mg IV over 1 h q4wks on the same day, or CON administration over 1 h. The serum pharmacokinetic profile of SEQ versus CON of durvalumab and tremelimumab administration was also evaluated. Results 14 patients either received SEQ (n = 7pts) or CON (n = 7 pts). There were no infusion related reactions. Drug related adverse events (AEs) were mainly low grade and manageable, and comparable in frequency between SEQ/CON- fatigue (43%/57%), rash (43%/43%), pruritus (43%/29%) and nausea (14%/29%). One patient in each cohort discontinued treatment due to toxicity. The PK profiles of durvalumab and tremelimumab were similar between CON and SEQ, and to historical reference data. Conclusions Concurrent administration of durvalumab and tremelimumab over 1 h is safe with a comparable PK profile to sequential administration.
Collapse
MESH Headings
- Adult
- Aged
- Antibodies, Monoclonal/administration & dosage
- Antibodies, Monoclonal/adverse effects
- Antibodies, Monoclonal/blood
- Antibodies, Monoclonal/pharmacokinetics
- Antibodies, Monoclonal, Humanized/administration & dosage
- Antibodies, Monoclonal, Humanized/adverse effects
- Antibodies, Monoclonal, Humanized/blood
- Antibodies, Monoclonal, Humanized/pharmacokinetics
- Antineoplastic Agents, Immunological/administration & dosage
- Antineoplastic Agents, Immunological/adverse effects
- Antineoplastic Agents, Immunological/blood
- Antineoplastic Agents, Immunological/pharmacokinetics
- Antineoplastic Combined Chemotherapy Protocols/administration & dosage
- Antineoplastic Combined Chemotherapy Protocols/adverse effects
- Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics
- Female
- Humans
- Immune Checkpoint Inhibitors/administration & dosage
- Immune Checkpoint Inhibitors/adverse effects
- Immune Checkpoint Inhibitors/blood
- Immune Checkpoint Inhibitors/pharmacokinetics
- Male
- Middle Aged
- Neoplasms/blood
- Neoplasms/drug therapy
- Neoplasms/metabolism
Collapse
Affiliation(s)
- J Nehra
- Canadian Cancer Trials Group, Queen's University, 10 Stuart Street, Kingston, ON, K7L3N6, Canada
| | - P A Bradbury
- Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada
| | - P M Ellis
- Department of Oncology - Division of Medical Oncology, Juravinski Cancer Centre, Hamilton, Canada
| | - J Laskin
- Division of Medical Oncology, BCCA Vancouver Cancer Centre, Vancouver, Canada
| | - C Kollmannsberger
- Division of Medical Oncology, BCCA Vancouver Cancer Centre, Vancouver, Canada
| | - D Hao
- Department of Oncology - Section of Medical Oncology, Tom Baker Cancer Centre University of Calgary, Calgary, Canada
| | - R A Juergens
- Department of Oncology - Division of Medical Oncology, Juravinski Cancer Centre, Hamilton, Canada
| | - G Goss
- Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, Canada
| | - P Wheatley-Price
- Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, Canada
| | - S J Hotte
- Department of Oncology - Division of Medical Oncology, Juravinski Cancer Centre, Hamilton, Canada
| | - K Gelmon
- Division of Medical Oncology, BCCA Vancouver Cancer Centre, Vancouver, Canada
| | - A V Tinker
- Division of Medical Oncology, BCCA Vancouver Cancer Centre, Vancouver, Canada
| | - P Brown-Walker
- Canadian Cancer Trials Group, Queen's University, 10 Stuart Street, Kingston, ON, K7L3N6, Canada
| | - I Gauthier
- Canadian Cancer Trials Group, Queen's University, 10 Stuart Street, Kingston, ON, K7L3N6, Canada
| | - D Tu
- Canadian Cancer Trials Group, Queen's University, 10 Stuart Street, Kingston, ON, K7L3N6, Canada
| | - X Song
- Clinical Pharmacology & Safety Sciences, AstraZeneca, Gaithersburg, MD, USA
| | - A Khan
- Clinical Pharmacology & Safety Sciences, AstraZeneca, Gaithersburg, MD, USA
| | - Lesley Seymour
- Canadian Cancer Trials Group, Queen's University, 10 Stuart Street, Kingston, ON, K7L3N6, Canada.
| | - M Smoragiewicz
- Canadian Cancer Trials Group, Queen's University, 10 Stuart Street, Kingston, ON, K7L3N6, Canada
| |
Collapse
|
8
|
Shenkier T, Lohrisch C, Simmons C, Dotts A, McTaggart-Cowan H, Houlihan E, Johnston C, Le D, Gelmon K, Chia S. After breast cancer: A nurse practitioner led model of care for women on adjuvant endocrine treatment. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz101.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
9
|
Moreno V, Luke J, Gelmon K, Joshua A, Varga A, Desai J, Markman B, Gomez-Roca C, De Braud F, Patel S, Carlino M, Siu L, Curigliano G, Liu Z, Ishii Y, Wind-Rotolo M, Basciano P, Azrilevich A, Tabernero J. Combination of the indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i) BMS-986205 with nivolumab (nivo): Updated safety across all tumors and efficacy in advanced bladder cancer (advBC) by patient (pt) subgroup. ACTA ACUST UNITED AC 2019. [DOI: 10.1016/s1569-9056(19)31087-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
10
|
Arnaout A, Lee J, Gelmon K, Poirier B, Lu F, Akra M, Boileau J, Tonkin K, Li H, Illman C, Simmons C, Grenier D. Neoadjuvant Therapy for Breast Cancer: Updates and Proceedings From the Seventh Annual Meeting of the Canadian Consortium for Locally Advanced Breast Cancer. Curr Oncol 2018. [DOI: 10.3747/co.25.4153] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Therapy for breast cancer involves a complex interplay of three main treatment modalities: surgery, systemic therapy, and radiation therapy. The Canadian Consortium for Locally Advanced Breast Cancer (LABC) was established with the goal to convene a strong multidisciplinary team of breast oncology clinicians and scientists who are dedicated to the advancement of LABC research and treatment, with a vision to drive progress through increased collaboration across disciplines and throughout Canada. The most recent meeting in May 2017 highlighted the latest evidence and literature about the optimal use of neoadjuvant systemic therapy in breast cancer. There is a need for increased clinical and scientific collaboration and the development of guidelines for the use of emerging treatment strategies. The interactive meeting sessions fostered unique opportunities for academic debate and nurtured collaboration between the attendees.
Collapse
|
11
|
Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortés J, Curigliano G, Diéras V, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen BV, Ohno S, Pagani O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†. Ann Oncol 2018; 29:1634-1657. [PMID: 30032243 PMCID: PMC7360146 DOI: 10.1093/annonc/mdy192] [Citation(s) in RCA: 761] [Impact Index Per Article: 126.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Affiliation(s)
- F Cardoso
- European School of Oncology (ESO), European Society for Medical Oncology (ESMO) and Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal.
| | - E Senkus
- European Society for Medical Oncology (ESMO) and Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
| | - A Costa
- European School of Oncology, Milan, Italy
| | | | - M Aapro
- Oncology Department, Clinique de Genolier, Genolier, Switzerland
| | - F André
- Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
| | - N Harbeck
- Breast Centre, Department of Obstetrics and Gynaecology, University of Munich (LMU), Munich, Germany
| | - B Aguilar Lopez
- Direction Office, ULACCAM (Union Latinoamericana Contra el Cáncer de la Mujer), Mexico DF, Mexico
| | - C H Barrios
- Department of Oncology, PURCS School of Medicine, Porto Alegre, Brazil
| | - J Bergh
- Department of Oncology-Pathology, Karolinska Institute & University Hospital, Stockholm, Sweden
| | - L Biganzoli
- European Society of Breast Cancer Specialists (EUSOMA) and Department of Medical Oncology, Nuovo Ospedale di Prato - Istituto Toscano Tumori, Prato, Italy
| | | | - M J Cardoso
- Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation and Nova Medical School, Lisbon, Portugal
| | - L A Carey
- Department of Hematology and Oncology, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, USA
| | - J Cortés
- Department of Oncology, Vall d' Hebron University, Barcelona, Spain
| | - G Curigliano
- Division of Early Drug Development, Department of Oncology and Hemato-Oncology, European Institute of Oncology, University of Milano, Milano, Italy
| | - V Diéras
- Gynaecology and Breast Department, Centre Eugène Marquis, Rennes, France
| | - N S El Saghir
- Breast Center of Excellence, American University of Beirut Medical Center, Beirut, Lebanon
| | - A Eniu
- Breast Cancer Department, Cancer Institute Ion Chiricuta, Cluj-Napoca, Romania
| | - L Fallowfield
- SHORE-C, Brighton & Sussex Medical School, University of Sussex, Brighton, UK
| | - P A Francis
- Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - K Gelmon
- Medical Oncology Department, BC Cancer Agency, Vancouver, Canada
| | | | - B Kaufman
- Department of Oncology, Sheba Medical Center, Ramat Gan, Israel
| | - S Koppikar
- Department of Medical Oncology, Bombay Hospital Institute of Medical Sciences, Mumbai, India
| | - I E Krop
- Breast Oncology Center Dana-Farber Cancer Institute, Boston, USA
| | - M Mayer
- Advanced BC.org, New York, USA
| | - G Nakigudde
- Advocacy Department, UWOCASO (Uganda Women's Cancer Support Organization), Kampala, Uganda
| | - B V Offersen
- European Society of Radiation Oncology (ESTRO) and Department of Experimental Clinical Oncology & Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
| | - S Ohno
- Cancer Institute Hospital, Breast Oncology Centre, Tokyo, Japan
| | - O Pagani
- Institute of Oncology of Southern Switzerland, Geneva University Hospitals, Swiss Group for Clinical Cancer Research (SAKK), International Breast Cancer Study Group (IBCSG), Bellinzona, Switzerland
| | - S Paluch-Shimon
- Oncology Institute, Shaare Zedek Medical Centre, Jerusalem, Israel
| | - F Penault-Llorca
- Department of Pathology, Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - A Prat
- IDIBAPS (Institut d'Investigacions Biomèdiques August Pi iSunyer), Hospital Clínic of Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumor, Barcelona, Spain
| | - H S Rugo
- Breast Oncology Clinical Trials Education, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA
| | - G W Sledge
- Oncology Division, Stanford University Medical Center, Stanford, USA
| | - D Spence
- Policy Department, Breast Cancer Network Australia, Camberwell, VIC, Australia
| | - C Thomssen
- Department of Gynaecology, Martin Luther University Halle-Wittenburg, Halle, Germany
| | - D A Vorobiof
- Oncology Department, Sandton Oncology Centre, Johannesburg, South Africa
| | - B Xu
- Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
| | - L Norton
- Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York
| | - E P Winer
- Dana-Farber Cancer Institute, Susan Smith Center for Women's Cancers, Breast Oncology Center, Boston, USA
| |
Collapse
|
12
|
Jones MR, Lim H, Shen Y, Pleasance E, Ch'ng C, Reisle C, Leelakumari S, Zhao C, Yip S, Ho J, Zhong E, Ng T, Ionescu D, Schaeffer DF, Mungall AJ, Mungall KL, Zhao Y, Moore RA, Ma Y, Chia S, Ho C, Renouf DJ, Gelmon K, Jones SJM, Marra MA, Laskin J. Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer. Ann Oncol 2018; 28:3092-3097. [PMID: 28950338 DOI: 10.1093/annonc/mdx523] [Citation(s) in RCA: 72] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Background NRG1 fusion-positive lung cancers have emerged as potentially actionable events in lung cancer, but clinical support is currently limited and no evidence of efficacy of this approach in cancers beyond lung has been shown. Patients and methods Here, we describe two patients with advanced cancers refractory to standard therapies. Patient 1 had lung adenocarcinoma and patient 2 cholangiocarcinoma. Whole-genome and transcriptome sequencing were carried out for these cases with select findings validated by fluorescence in situ hybridization. Results Both tumors were found to be positive for NRG1 gene fusions. In patient 1, an SDC4-NRG1 gene fusion was detected, similar gene fusions having been described in lung cancers previously. In patient 2, a novel ATP1B1-NRG1 gene fusion was detected. Cholangiocarcinoma is not a disease type in which NRG1 fusions had been described previously. Integrative genome analysis was used to assess the potential functional significance of the detected genomic events including the gene fusions, prioritizing therapeutic strategies targeting the HER-family of growth factor receptors. Both patients were treated with the pan HER-family kinase inhibitor afatinib and both displayed significant and durable response to treatment. Upon progression sites of disease were sequenced. The lack of obvious genomic events to describe the disease progression indicated that broad transcriptomic or epigenetic mechanisms could be attributed to the lack of prolonged response to afatinib. Conclusion These observations lend further support to the use of pan HER-tyrosine kinase inhibitors for the treatment of NRG1 fusion-positive in both cancers of lung and hepatocellular origin and indicate more broadly that cancers found to be NRG1 fusion-positive may benefit from such a clinical approach regardless of their site of origin. Clinical trial information Personalized Oncogenomics (POG) Program of British Columbia: Utilization of Genomic Analysis to Better Understand Tumour Heterogeneity and Evolution (NCT02155621).
Collapse
Affiliation(s)
- M R Jones
- Canada's Michael Smith Genome Sciences Centre
| | - H Lim
- Division of Medical Oncology, BC Cancer Agency, Vancouver
| | - Y Shen
- Canada's Michael Smith Genome Sciences Centre
| | - E Pleasance
- Canada's Michael Smith Genome Sciences Centre
| | - C Ch'ng
- Canada's Michael Smith Genome Sciences Centre
| | - C Reisle
- Canada's Michael Smith Genome Sciences Centre
| | | | - C Zhao
- Canada's Michael Smith Genome Sciences Centre
| | - S Yip
- Department of Pathology & Laboratory Medicine, Vancouver General Hospital, Vancouver
| | - J Ho
- Department of Pathology & Laboratory Medicine, Vancouver General Hospital, Vancouver
| | - E Zhong
- Department of Pathology & Laboratory Medicine, Vancouver General Hospital, Vancouver
| | - T Ng
- Department of Pathology & Laboratory Medicine, Vancouver General Hospital, Vancouver
| | - D Ionescu
- Department of Pathology & Laboratory Medicine, BC Cancer Agency, Vancouver
| | - D F Schaeffer
- Department of Pathology & Laboratory Medicine, Vancouver General Hospital, Vancouver
| | - A J Mungall
- Canada's Michael Smith Genome Sciences Centre
| | - K L Mungall
- Canada's Michael Smith Genome Sciences Centre
| | - Y Zhao
- Canada's Michael Smith Genome Sciences Centre
| | - R A Moore
- Canada's Michael Smith Genome Sciences Centre
| | - Y Ma
- Canada's Michael Smith Genome Sciences Centre
| | - S Chia
- Division of Medical Oncology, BC Cancer Agency, Vancouver
| | - C Ho
- Division of Medical Oncology, BC Cancer Agency, Vancouver
| | - D J Renouf
- Division of Medical Oncology, BC Cancer Agency, Vancouver
| | - K Gelmon
- Division of Medical Oncology, BC Cancer Agency, Vancouver
| | - S J M Jones
- Canada's Michael Smith Genome Sciences Centre.,Department of Medical Genetics, University of British Columbia, Vancouver.,Department of Molecular Biology and Biochemistry, Simon Fraser University, Vancouver, Canada
| | - M A Marra
- Canada's Michael Smith Genome Sciences Centre.,Department of Medical Genetics, University of British Columbia, Vancouver
| | - J Laskin
- Division of Medical Oncology, BC Cancer Agency, Vancouver
| |
Collapse
|
13
|
Hilton J, Cescon D, Bedard P, Ritter H, Tu D, Soong J, Gelmon K, Aparicio S, Seymour L. CCTG IND.231: A phase 1 trial evaluating CX-5461 in patients with advanced solid tumors. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy048.003] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
14
|
Gelmon K, Walker GP, Fisher GV. Abstract OT3-04-04: LUCY: A phase IIIb, single-arm, open-label multicenter study of olaparib in patients with HER2-negative metastatic breast cancer and a germline BRCA1/2 mutation. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-ot3-04-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Olaparib (Lynparza) is a PARP inhibitor with activity in patients with advanced cancers who have a germline BRCA1 and/or BRCA2 (gBRCA) mutation and is licensed for use in gBRCA-mutated recurrent ovarian cancer. The Phase III OlympiAD trial (NCT02000622) in HER2-negative metastatic breast cancer (mBC) patients with a gBRCA mutation showed a significant progression-free survival (PFS) improvement in favor of olaparib compared with physician's choice of chemotherapy treatment (hazard ratio [HR] 0.58; 95% confidence interval [CI] 0.43–0.80; P<0.001; 7.0 vs 4.2 months, respectively) (Robson et al. NEJM 2017). The LUCY trial (EudraCT number: 2017-001054-34) has been initiated to further evaluate the clinical effectiveness of olaparib in a real-world setting, and to help inform and guide clinical practice.
Trial design
LUCY is an open-label, single-arm, multicenter, international Phase IIIb trial. All patients will be treated with open-label olaparib tablets (300 mg twice daily) until disease progression, unacceptable toxicity, or other discontinuation criteria.
Eligibility criteria
Eligible patients aged ≥18 years will have a gBRCA mutation and HER2-negative mBC. Patients are required to have received a prior taxane or anthracycline in either the adjuvant or metastatic setting, but should not have received >1 line of chemotherapy in the metastatic setting. Hormone receptor-positive patients are also required to have received and progressed with ≥1 prior endocrine therapy. Patients will be required to have an expected survival of >6 months.
Objectives
The primary objective is to evaluate the clinical effectiveness of olaparib through investigator-defined assessment of PFS (radiological, symptomatic, or clear progression of non-measurable disease). Secondary objectives will include assessments of overall survival (OS), time to first/second subsequent therapy, time to second progression and time to study treatment discontinuation, as well as assessment of clinical response rate and duration of clinical response. Safety and tolerability will also be described.
Statistical methods
Approximately 2500 patients will be screened to identify 250 patients with a gBRCA mutation. The primary analysis of PFS will be performed after 160 progression events: assuming a median PFS of 7 months, the predicted 95% CI for the median is 6.0–8.2 months. Analysis of OS and updated PFS will be performed after 160 deaths: assuming a median OS of 19 months, the predicted 95% CI for the median is 16.3–22.2 months. PFS and OS will be summarized using a Kaplan–Meier plot, from which the median and 95% CI data will be calculated.
Present accrual
Screening is expected to take place across ˜180 sites in 17 countries.
Summary
LUCY will provide further data on the efficacy of olaparib in the real-world setting of mBC in patients with gBRCA mutation.
Citation Format: Gelmon K, Walker GP, Fisher GV. LUCY: A phase IIIb, single-arm, open-label multicenter study of olaparib in patients with HER2-negative metastatic breast cancer and a germline BRCA1/2 mutation [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT3-04-04.
Collapse
Affiliation(s)
- K Gelmon
- British Columbia Cancer Agency, Vancouver, Canada; AstraZeneca, Cambridge, United Kingdom
| | - GP Walker
- British Columbia Cancer Agency, Vancouver, Canada; AstraZeneca, Cambridge, United Kingdom
| | - GV Fisher
- British Columbia Cancer Agency, Vancouver, Canada; AstraZeneca, Cambridge, United Kingdom
| |
Collapse
|
15
|
Loibl S, Barinoff J, Seiler S, Decker T, Denkert C, Hardy-Bessard AC, Senkus-Konefka E, Cognetti F, Palmieri C, Gelmon K, Luebbe K, Furlanetto J, Mueller V, Mundhenke C, Schmidt M, von Minckwitz G, Uhlig M, Burchardi N, Thill M. Abstract OT3-05-04: A randomized, open-label, multi-center phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy-based treatment strategy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer in a real world setting (PADMA). Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-ot3-05-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Although endocrine therapy (ET) is recommended as first-line therapy for hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC) up to 50% of patients receive chemotherapy in this setting. Meanwhile new targeted treatment options for combination with ET have been developed and endocrine-based therapy with the CDK4/6 inhibitor Palbociclib (P) improves the progression free survival (PFS) of ET alone by about 50%. So far, there is no data comparing chemotherapy with or without maintenance ET and ET in combination with P as first-line therapy. Patients included in clinical trials are often criticized not to mirror the general breast cancer population and every-day clinical practice due to rigid inclusion and exclusion criteria, limited number of treatment options, strict monitoring intervals and study assessments.
Methods:
PADMA trial is a so called low intervention trial with no rigid inclusion and exclusion criteria, and study assessments.Patients with first-line HR+/HER2- MBC who are candidate for mono-chemotherapy will be eligible to receive either P plus ET per label or mono-chemotherapy per investigator´s choice with or without maintenance ET (1:1 randomization). Primary objective is to compare the time-to-treatment failure (TTF) for patients randomized to receive the mono-chemotherapy treatment strategy versus those randomized to receive P and ET. TTF is defined as time from randomization to discontinuation of treatment due to disease progression, treatment toxicity, patient's preference, or death. Main secondary objectives are progression free survival, overall survival at 36 months, amongst other time to event endpoints as well as toxicity and compliance. All patients receive a specific mobile device (PADMA-Phone) and a validated wearable device (ActiWatch) in order to collect data regarding sleep and activity levels, patient well-being and health care utilization (number and duration of phone calls, and patient visits to investigator site) for assessment of daily monitoring treatment impact (DMTI).
Results:
Overall, 360 patients will be accrued to show an improved TTF for P in combination with ET compared to mono-chemotherapy of investigator´s choice with or without maintenance ET. Recruitment will start in QIII/2017 and is planned for approximately 18 months in 100 sites in Germany, Spain, Poland, Italy, France, UK and Canada.
Conclusions:
The aim of PADMA is to demonstrate that an endocrine-based strategy consisting of ET plus P is superior to a chemotherapy-based strategy as first-line therapy in women with HR+/HER2- MBC in a real world setting. Assessment of patient-reported outcome, health care utilization, and sleep and activity levels will deliver important information on the differences between endocrine-based and chemotherapy-based treatment.
Citation Format: Loibl S, Barinoff J, Seiler S, Decker T, Denkert C, Hardy-Bessard A-C, Senkus-Konefka E, Cognetti F, Palmieri C, Gelmon K, Luebbe K, Furlanetto J, Mueller V, Mundhenke C, Schmidt M, von Minckwitz G, Uhlig M, Burchardi N, Thill M. A randomized, open-label, multi-center phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy-based treatment strategy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer in a real world setting (PADMA) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT3-05-04.
Collapse
Affiliation(s)
- S Loibl
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - J Barinoff
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - S Seiler
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - T Decker
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - C Denkert
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - A-C Hardy-Bessard
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - E Senkus-Konefka
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - F Cognetti
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - C Palmieri
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - K Gelmon
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - K Luebbe
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - J Furlanetto
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - V Mueller
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - C Mundhenke
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - M Schmidt
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - G von Minckwitz
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - M Uhlig
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - N Burchardi
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| | - M Thill
- German Breast Group; Charité Universitätsmedizin Berlin; Onkologie Ravensburg; Centre Armoricaine d'Oncologie; Medical University of Gdańsk; Istituto Nazionale Tumori Regina Elena; University of Liverpool; University of British Columbia; Diakovere Henriettenstiftung; University Hospital Eppendorf Frauenklinik; University of Kiel; Johannes Gutenberg Universität; Agaplesion Markus Hospital
| |
Collapse
|
16
|
Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol 2017; 28:3111. [PMID: 28327998 PMCID: PMC5834023 DOI: 10.1093/annonc/mdx036] [Citation(s) in RCA: 136] [Impact Index Per Article: 19.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
17
|
Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios C, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso M, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart M, Pierga J, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. Corrigendum to “3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)” [Breast 31 (February 2017) 244–259]. Breast 2017; 32:269-270. [DOI: 10.1016/j.breast.2017.01.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
18
|
den Brok WL, Chia S, Kalloger S, Bates C, Aparicio S, Mar C, Gelmon K, Eirew P. Abstract P4-06-10: Rates of successful engraftment in breast cancer xenograft models based on tissue type: Primary vs relapsed disease. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-06-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: As we have published expertise in breast cancer xenograft models and clonal dynamics, our aim was to explore rates of engraftment based on type of tissue for attempted xenografting (primary vs relapsed/metastatic disease) and clinical breast biomarker subtype.
Methods: Tissue from patients (pts) enrolled in a locally advanced/metastatic study and a breast tumour tissue repository (ie. resectable primaries) between Sept. 2008 and July 2015 underwent xenografting using NodScid/IL2rgKO (NSG) mice. Xenografts were passaged when tumour volume reached 1 cm3. Mice with no engraftment after 12 months (mos) were sacrificed. Pt charts were reviewed to determine biomarker status (hormone receptor [HR], HER2), date and type of tissue collection for xenografting. Prediction of successful engraftment based on tissue type and biomarker status was performed using nominal logistic regression.
Results: A total of 70 tissue samples with known engraftment status were included in the analysis: 51 from primary breast tumour, 10 from relapsed disease (dz) with ≤ 1 line of therapy in the advanced setting and 9 from relapsed dz with > 1 line of therapy in the advanced setting. Tumours from pts treated with > 1 line of therapy were more likely to engraft compared to primary or recurrent dz with ≤ 1 line of therapy (89%, 35%, and 40% respectively; p=.008). HR- primary tumours were more likely to engraft compared to HR+ primary tumours: 71% of HR-/HER2- (triple negative) and 67% of HR-/HER2+ tumours versus 4% of HR+/HER2- and 38% of HR+/HER2+ tumours; p<.0001. Combining all tissue types, HR- tumours were more likely to engraft compared to HR+ tumours: 76% of HR-/HER2- and 67% of HR-/HER2+ tumours versus 37% of HR+/HER2+ and 22% of HR+/HER2- tumours; p=.0007. Table 1 shows the rate of engraftment for each tissue type and biomarker status. Combining these 2 variables predicts engraftment in 80% of cases.
Conclusion: This preliminary study highlights potential differences in successful xenoengraftment based on biomarker status at diagnosis and type of tissue, primary vs relapsed tumour, the latter suggesting that the underlying biology of primary or first relapsed recurrent disease is distinct from more refractory disease, and warrants further exploration. This work is ongoing. (Funded by CBCRA, BCCF)
Engraftment of primary tumour vs relapsed disease Primary tumour (N=52) N, (%)Recurrent disease and ≤ 1 line of Rx in advanced setting (N=10) N, (%)Recurrent disease and > 1 line of Rx in advanced setting (N=9) N, (%)Engraftment Yes18 (35)4 (40)8 (89)HR-/HER2-10 (55)1 (25)2 (25)HR-/HER2+4 (22)1 (25)1 (13)HR+/HER2+3 (17)00HR+/HER2-1 (6)2 (50)5 (62)Engraftment No33 (65)6 (60)1 (11)HR-/HER2-4 (12)00HR-/HER2+2 (6)1 (17)0HR+/HER2+5 (15)00HR+/HER2-22 (67)5 (83)1 (100)
Citation Format: den Brok W-l, Chia S, Kalloger S, Bates C, Aparicio S, Mar C, Gelmon K, Eirew P. Rates of successful engraftment in breast cancer xenograft models based on tissue type: Primary vs relapsed disease [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-06-10.
Collapse
Affiliation(s)
- W-l den Brok
- BC Cancer Agency, Vancouver, BC, Canada; BC Cancer Research Centre, Vancouver, BC, Canada
| | - S Chia
- BC Cancer Agency, Vancouver, BC, Canada; BC Cancer Research Centre, Vancouver, BC, Canada
| | - S Kalloger
- BC Cancer Agency, Vancouver, BC, Canada; BC Cancer Research Centre, Vancouver, BC, Canada
| | - C Bates
- BC Cancer Agency, Vancouver, BC, Canada; BC Cancer Research Centre, Vancouver, BC, Canada
| | - S Aparicio
- BC Cancer Agency, Vancouver, BC, Canada; BC Cancer Research Centre, Vancouver, BC, Canada
| | - C Mar
- BC Cancer Agency, Vancouver, BC, Canada; BC Cancer Research Centre, Vancouver, BC, Canada
| | - K Gelmon
- BC Cancer Agency, Vancouver, BC, Canada; BC Cancer Research Centre, Vancouver, BC, Canada
| | - P Eirew
- BC Cancer Agency, Vancouver, BC, Canada; BC Cancer Research Centre, Vancouver, BC, Canada
| |
Collapse
|
19
|
Liu S, Chen B, Burugu S, Leung S, Gao D, Virk S, Kos Z, Parulekar WR, Shepherd L, Gelmon K, Nielsen TO. Abstract P1-09-08: Predictive effect of cytotoxic tumor infiltrating lymphocytes in HER2-positive metastatic breast cancer: A correlative study with CCTG MA.31. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p1-09-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background and Objectives: The presence of tumor infiltrating lymphocytes (TILs), particularly CD8+ cytotoxic T-cells, has been associated with improved prognosis in patients with HER2+ breast cancer. Increasing levels of TILs also appear to predict response to adjuvant trastuzumab in early breast cancer, although they did not predict benefit of combined trastuzumab-lapatinib neoadjuvant dual therapy over monotherapy in NeoALLTO. CCTG MA.31 randomized 652 women with HER2+ metastatic breast cancer to treatment with trastuzumab (T) vs. lapatinib (L), in combination with taxane (Tax) chemotherapy for 24 weeks, followed by the same HER2-targeted monotherapy. Final results from MA.31 found trastuzumab was superior to lapatinib for the primary endpoint of progression free survival (PFS): the hazard ratio (HR) for lapatinib to trastuzumab was 1.37 (95% CI, 1.13-1.65). Although both agents block HER2 signaling, trastuzumab has additional mechanisms of action via the immune system. We hypothesized that TIL levels may predict response to HER2-targeted therapy (trastuzumab vs. lapatinib).
Methods: MA.31 included HER2+ metastatic breast cancer patients, median age 55 years, and median follow-up 21.5 months. Overall TILs were counted per published guidelines on the original H&E stained sections used for pathology review at study entry. Immunohistochemistry (IHC) was performed on unstained sections from tissue microarrays or individual formalin-fixed paraffin-embedded blocks to test expression of lymphocyte biomarkers CD8, FOXP3, CD56 and PD-1 on stromal and intra-tumoral TILs (sTILs, iTILs). Statistical analysis was conducted by CCTG for a total of 9 prespecified biomarker tests. Associations of TILs with PFS were evaluated by univariate stratified log-rank test with graphical Kaplan-Meier curves, and by stratified multivariate Cox proportional hazards regression analysis. Predictive effect was examined with a test of interaction between treatment allocation and biomarker classification (high vs. low, using pre-established cutpoints).
Results: Of the 652 cases, 614 had slides for overall TIL assessment and 427 for IHC biomarker assessments. In this correlative study set, superiority of trastuzumab over lapatinib for PFS was confirmed in multivariate analysis (LTax/T vs. TTax/L: HR = 2.55, 95% CI = 1.43-4.55, p = 0.001). TIL counts by H&E were neither prognostic nor predictive in this set of metastatic HER2+ breast cancers. Lymphocyte IHC markers were not prognostic. However, prespecified stratified univariate analysis detected a significantly higher risk for lapatinib over trastuzumab (HR = 2.94, 95% CI = 1.40-6.17, p = 0.003) in patients with low CD8+ sTIL (< 3) than was observed among those with high CD8+ sTIL (HR = 1.36, 95% CI = 1.05-1.75, p = 0.019). This differential effect was confirmed in multivariate analysis (interaction test p = 0.042). The other tested biomarkers did not demonstrate significant predictive effects.
Conclusions: In this correlative study of metastatic HER2+ breast cancer, a low level of pre-existing stromal cytotoxic T cell infiltration predicts women who benefit most from trastuzumab over lapatinib. Overall TIL counts were neither prognostic nor predictive.
Citation Format: Liu S, Chen B, Burugu S, Leung S, Gao D, Virk S, Kos Z, Parulekar WR, Shepherd L, Gelmon K, Nielsen TO. Predictive effect of cytotoxic tumor infiltrating lymphocytes in HER2-positive metastatic breast cancer: A correlative study with CCTG MA.31 [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-09-08.
Collapse
Affiliation(s)
- S Liu
- University of British Columbia and Vancouver Coastal Health Research Institute; Canadian Cancer Trials Group; University of Ottawa; British Columbia Cancer Agency
| | - B Chen
- University of British Columbia and Vancouver Coastal Health Research Institute; Canadian Cancer Trials Group; University of Ottawa; British Columbia Cancer Agency
| | - S Burugu
- University of British Columbia and Vancouver Coastal Health Research Institute; Canadian Cancer Trials Group; University of Ottawa; British Columbia Cancer Agency
| | - S Leung
- University of British Columbia and Vancouver Coastal Health Research Institute; Canadian Cancer Trials Group; University of Ottawa; British Columbia Cancer Agency
| | - D Gao
- University of British Columbia and Vancouver Coastal Health Research Institute; Canadian Cancer Trials Group; University of Ottawa; British Columbia Cancer Agency
| | - S Virk
- University of British Columbia and Vancouver Coastal Health Research Institute; Canadian Cancer Trials Group; University of Ottawa; British Columbia Cancer Agency
| | - Z Kos
- University of British Columbia and Vancouver Coastal Health Research Institute; Canadian Cancer Trials Group; University of Ottawa; British Columbia Cancer Agency
| | - WR Parulekar
- University of British Columbia and Vancouver Coastal Health Research Institute; Canadian Cancer Trials Group; University of Ottawa; British Columbia Cancer Agency
| | - L Shepherd
- University of British Columbia and Vancouver Coastal Health Research Institute; Canadian Cancer Trials Group; University of Ottawa; British Columbia Cancer Agency
| | - K Gelmon
- University of British Columbia and Vancouver Coastal Health Research Institute; Canadian Cancer Trials Group; University of Ottawa; British Columbia Cancer Agency
| | - TO Nielsen
- University of British Columbia and Vancouver Coastal Health Research Institute; Canadian Cancer Trials Group; University of Ottawa; British Columbia Cancer Agency
| |
Collapse
|
20
|
Diéras V, Rugo HS, Gelmon K, Finn RS, Cristofanilli M, Loi S, Colleoni M, Lu D, Gauthier E, Huang-Bartlett C, Turner NC, Schnell P. Abstract P4-22-07: Long-term safety of palbociclib in combination with endocrine therapy in treatment-naive and previously treated women with HR+ HER2– advanced breast cancer: A pooled analysis from randomized phase 2 and 3 studies. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-22-07] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Palbociclib (PAL) is a selective and reversible oral cyclin-dependent kinase 4 and 6 inhibitor. Large randomized phase (ph) 2 and 3 trials showed significant improvement in progression-free survival (PFS) when PAL was combined with endocrine therapy (ET) vs ET alone in treatment (trt)-naive and previously treated hormone receptor?positive human epidermal growth factor receptor 2?negative (HR+ HER2–) advanced breast cancer (ABC) patients (pts). The median PFS with PAL+ET is >2 years as a first-line therapy for ABC and 11.2 mo in endocrine-resistant ABC. We evaluated the long-term safety in PALOMA-1, -2, and -3.
Methods: We analyzed the tolerability of PAL in combination with ET in 3 randomized trials. Pts untreated for ABC were randomized to receive PAL+letrozole (LET) vs LET alone in PALOMA-1 (ph 2, open-label; 1:1) or randomized to receive PAL+LET vs placebo (PBO)+LET in PALOMA-2 (ph 3, double-blind; 2:1). PALOMA-3 included pts who progressed on prior ET, randomized to receive PAL+fulvestrant (FUL) or PBO+FUL (ph 3, double-blind; 2:1). Safety assessments, including a complete blood count, were done at baseline, on D1 of each cycle, and on D14 of the first 2 cycles. We evaluated adverse events (AEs) by 6-mo intervals (out to 36 mo) and cumulatively (12-, 24-, and 36-mo time points), and assessed latency (event onset) of pertinent adverse drug reactions (ADRs) in all pts treated in PALOMA-1, -2, and -3.
Results: A total of 1352 pts were pooled for this analysis; 872 pts received PAL+ET (527 pts, PAL+LET; 345 pts, PAL+FUL). Median duration of trt was 421 days in PALOMA-1 (January 2015), 603 days in PALOMA-2 (February 2016), and 330 days in PALOMA-3 (July 2015). PAL+LET was received by 119 pts as first-line trt in PALOMA-1 and 2 for 24–<30 months and 11 pts were treated for >36 mo. PAL+FUL was received by 140 pts for >12 mo as second-line trt in PALOMA-3. The most commonly reported ADRs across all studies were neutropenia, fatigue, nausea, anemia, and leukopenia. The 6-mo-interval analyses of the most common (>15%) AEs (by preferred term [PT]) from PALOMA-1, -2, and -3 indicated that these AEs were reported with the highest frequency during the first 6-mo interval and typically decreased in incidence over time to 30–<36-mo; the most common hematologic AEs (clustered PTs) are shown (Table). The cumulative incidence of AEs after the first vs the second and third years showed similar frequencies of most AEs, including the most common ADRs.
Conclusions: Based on these long-term safety analyses, there is no evidence of specific cumulative or delayed toxicity resulting from prolonged trt with PAL+ET for HR+ HER2– ABC. This supports the ongoing investigation of PAL+ET in early breast cancer (NCT02513394).
Table. Pooled hematologic AEs: all grades and all causality clustered PTs reported for ≥10% of PAL+ET (LET/FUL)-treated ptsTime interval, mo0–<66–<1212–<1818–<2424–<3030–<36≥36Patients, N8726764912891192711TEAEs, % Neutropenia75.758.649.349.842.937.054.5Leukopenia40.027.416.711.87.611.118.2Anemia20.812.710.011.19.211.118.2Thrombocytopenia15.18.76.15.55.914.836.4TEAEs=treatment-emergent adverse events.
Sponsor: Pfizer.
Citation Format: Diéras V, Rugo HS, Gelmon K, Finn RS, Cristofanilli M, Loi S, Colleoni M, Lu D, Gauthier E, Huang-Bartlett C, Turner NC, Schnell P. Long-term safety of palbociclib in combination with endocrine therapy in treatment-naive and previously treated women with HR+ HER2– advanced breast cancer: A pooled analysis from randomized phase 2 and 3 studies [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-22-07.
Collapse
Affiliation(s)
- V Diéras
- Institut Curie, Paris, France; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; British Columbia Cancer Agency, Vancouver, BC, Canada; David Geffen School of Medicine, Los Angeles, CA; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, IL; Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; Istituto Europeo di Oncologia, Milan, Italy; Pfizer Inc, La Jolla, CA; Pfizer Inc, Collegeville, PA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; Pfizer Inc, New York, NY
| | - HS Rugo
- Institut Curie, Paris, France; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; British Columbia Cancer Agency, Vancouver, BC, Canada; David Geffen School of Medicine, Los Angeles, CA; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, IL; Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; Istituto Europeo di Oncologia, Milan, Italy; Pfizer Inc, La Jolla, CA; Pfizer Inc, Collegeville, PA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; Pfizer Inc, New York, NY
| | - K Gelmon
- Institut Curie, Paris, France; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; British Columbia Cancer Agency, Vancouver, BC, Canada; David Geffen School of Medicine, Los Angeles, CA; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, IL; Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; Istituto Europeo di Oncologia, Milan, Italy; Pfizer Inc, La Jolla, CA; Pfizer Inc, Collegeville, PA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; Pfizer Inc, New York, NY
| | - RS Finn
- Institut Curie, Paris, France; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; British Columbia Cancer Agency, Vancouver, BC, Canada; David Geffen School of Medicine, Los Angeles, CA; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, IL; Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; Istituto Europeo di Oncologia, Milan, Italy; Pfizer Inc, La Jolla, CA; Pfizer Inc, Collegeville, PA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; Pfizer Inc, New York, NY
| | - M Cristofanilli
- Institut Curie, Paris, France; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; British Columbia Cancer Agency, Vancouver, BC, Canada; David Geffen School of Medicine, Los Angeles, CA; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, IL; Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; Istituto Europeo di Oncologia, Milan, Italy; Pfizer Inc, La Jolla, CA; Pfizer Inc, Collegeville, PA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; Pfizer Inc, New York, NY
| | - S Loi
- Institut Curie, Paris, France; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; British Columbia Cancer Agency, Vancouver, BC, Canada; David Geffen School of Medicine, Los Angeles, CA; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, IL; Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; Istituto Europeo di Oncologia, Milan, Italy; Pfizer Inc, La Jolla, CA; Pfizer Inc, Collegeville, PA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; Pfizer Inc, New York, NY
| | - M Colleoni
- Institut Curie, Paris, France; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; British Columbia Cancer Agency, Vancouver, BC, Canada; David Geffen School of Medicine, Los Angeles, CA; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, IL; Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; Istituto Europeo di Oncologia, Milan, Italy; Pfizer Inc, La Jolla, CA; Pfizer Inc, Collegeville, PA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; Pfizer Inc, New York, NY
| | - D Lu
- Institut Curie, Paris, France; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; British Columbia Cancer Agency, Vancouver, BC, Canada; David Geffen School of Medicine, Los Angeles, CA; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, IL; Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; Istituto Europeo di Oncologia, Milan, Italy; Pfizer Inc, La Jolla, CA; Pfizer Inc, Collegeville, PA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; Pfizer Inc, New York, NY
| | - E Gauthier
- Institut Curie, Paris, France; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; British Columbia Cancer Agency, Vancouver, BC, Canada; David Geffen School of Medicine, Los Angeles, CA; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, IL; Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; Istituto Europeo di Oncologia, Milan, Italy; Pfizer Inc, La Jolla, CA; Pfizer Inc, Collegeville, PA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; Pfizer Inc, New York, NY
| | - C Huang-Bartlett
- Institut Curie, Paris, France; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; British Columbia Cancer Agency, Vancouver, BC, Canada; David Geffen School of Medicine, Los Angeles, CA; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, IL; Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; Istituto Europeo di Oncologia, Milan, Italy; Pfizer Inc, La Jolla, CA; Pfizer Inc, Collegeville, PA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; Pfizer Inc, New York, NY
| | - NC Turner
- Institut Curie, Paris, France; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; British Columbia Cancer Agency, Vancouver, BC, Canada; David Geffen School of Medicine, Los Angeles, CA; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, IL; Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; Istituto Europeo di Oncologia, Milan, Italy; Pfizer Inc, La Jolla, CA; Pfizer Inc, Collegeville, PA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; Pfizer Inc, New York, NY
| | - P Schnell
- Institut Curie, Paris, France; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; British Columbia Cancer Agency, Vancouver, BC, Canada; David Geffen School of Medicine, Los Angeles, CA; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, IL; Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; Istituto Europeo di Oncologia, Milan, Italy; Pfizer Inc, La Jolla, CA; Pfizer Inc, Collegeville, PA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; Pfizer Inc, New York, NY
| |
Collapse
|
21
|
Yeung C, Hilton J, Clemons M, Mazzarello S, Hutton B, Haggar F, Addison CL, Kuchuk I, Zhu X, Gelmon K, Arnaout A. Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review. Cancer Metastasis Rev 2017; 35:427-37. [PMID: 27405651 DOI: 10.1007/s10555-016-9631-3] [Citation(s) in RCA: 49] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Discordance in estrogen (ER), progesterone (PR), and HER2/neu status between primary breast tumours and metastatic disease is well recognized. In this review, we highlight how receptor discordance between primary tumours and paired metastasis can help elucidate the mechanism of metastasis but can also effect patient management and the design of future trials. Discordance rates and ranges were available from 47 studies (3384 matched primary and metastatic pairs) reporting ER, PR, and HER2/neu expression for both primary and metastatic sites. Median discordance rates for ER, PR, and HER2/neu were 14 % (range 0-67 %, IQR 9-25 %), 21 % (range 0-62 %, IQR 15-41 %), and 10 % (range 0-44 %, IQR 4-17 %), respectively. Loss of receptor expression was more common (9.17 %) than gain (4.51 %). Discordance rates varied amongst site of metastasis with ER discordance being highest in bone metastases suggesting that discordance is a true biological phenomenon. Discordance rates vary for both the biomarker and the metastatic site. Loss of expression is more common than gain. This can affect patient management as it can lead to a reduction in both the efficacy and availability of potential therapeutic agents. Future studies are recommended to explore both the mechanisms of discordance as well as its impact on patient outcome and management.
Collapse
MESH Headings
- Antineoplastic Agents, Hormonal/pharmacology
- Antineoplastic Agents, Hormonal/therapeutic use
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Biomarkers, Tumor
- Breast Neoplasms/genetics
- Breast Neoplasms/metabolism
- Breast Neoplasms/pathology
- Breast Neoplasms/therapy
- Female
- Gene Expression Regulation, Neoplastic
- Humans
- Molecular Targeted Therapy
- Neoplasm Metastasis
- Neoplasm Staging
- Prognosis
- Receptor, ErbB-2/genetics
- Receptor, ErbB-2/metabolism
- Receptors, Estrogen/genetics
- Receptors, Estrogen/metabolism
- Receptors, Progesterone/genetics
- Receptors, Progesterone/metabolism
- Treatment Outcome
Collapse
Affiliation(s)
- C Yeung
- Division of Surgical Oncology, University of Ottawa, Ottawa, Canada
| | - J Hilton
- Division of Medical Oncology, Department of Medicine, Ottawa Hospital Cancer Centre and University of Ottawa, Ottawa, Canada
- Ottawa Hospital Research Institute, Ottawa, Canada
| | - M Clemons
- Division of Medical Oncology, Department of Medicine, Ottawa Hospital Cancer Centre and University of Ottawa, Ottawa, Canada
- Ottawa Hospital Research Institute, Ottawa, Canada
| | - S Mazzarello
- Ottawa Hospital Research Institute, Ottawa, Canada
| | - B Hutton
- Ottawa Hospital Research Institute, Ottawa, Canada
| | - F Haggar
- Ottawa Hospital Research Institute, Ottawa, Canada
| | - C L Addison
- Ottawa Hospital Research Institute, Ottawa, Canada
| | - I Kuchuk
- Division of Medical Oncology, Department of Medicine, Ottawa Hospital Cancer Centre and University of Ottawa, Ottawa, Canada
| | - X Zhu
- Division of Medical Oncology, Department of Medicine, Ottawa Hospital Cancer Centre and University of Ottawa, Ottawa, Canada
| | - K Gelmon
- Division of Medical Oncology, British Columbia Cancer Agency, University of British Columbia, Vancouver, Canada
| | - A Arnaout
- Division of Surgical Oncology, University of Ottawa, Ottawa, Canada.
- Ottawa Hospital Research Institute, Ottawa, Canada.
| |
Collapse
|
22
|
Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol 2017; 28:16-33. [PMID: 28177437 PMCID: PMC5378224 DOI: 10.1093/annonc/mdw544] [Citation(s) in RCA: 258] [Impact Index Per Article: 36.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Affiliation(s)
- F. Cardoso
- European School of Oncology & Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal
| | - A. Costa
- European School of Oncology, Milan, Italy and European School of Oncology, Bellinzona, Switzerland
| | - E. Senkus
- Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
| | - M. Aapro
- Breast Center, Genolier Cancer Center, Genolier, Switzerland
| | - F. André
- Department of Medical Oncology, Gustave Roussy Institute, Villejuif, France
| | - C. H. Barrios
- Department of Medicine, PUCRS School of Medicine, Porto Alegre, Brazil
| | - J. Bergh
- Department of Oncology/Radiumhemmet, Karolinska Institutet & Cancer Center Karolinska and Karolinska University Hospital, Stockholm, Sweden
| | | | - L. Biganzoli
- Medical Oncology Department, Hospital of Prato, Prato, Italy
| | - M. J. Cardoso
- Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal
| | - L. Carey
- Department of Hematology and Oncology, UNC Lineberger Comprehensive Cancer Center
| | | | - G. Curigliano
- Division of Experimental Therapeutics, European Institute of Oncology, Milan, Italy
| | - V. Dieras
- Department of Medical Oncology, Institut Curie, Paris, France
| | - N. El Saghir
- NK Basile Cancer Institute Breast Center of Excellence, American University of Beirut, Beirut, Lebanon
| | - A. Eniu
- Department of Breast Tumors, Cancer Institute ‘I. Chiricuta’, Cluj-Napoca, Romania
| | - L. Fallowfield
- Brighton & Sussex Medical School, University of Sussex, Falmer, UK
| | - D. Fenech
- Breast Care Support Group, Europa Donna Malta, Mtarfa, Malta
| | - P. Francis
- Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - K. Gelmon
- BC Cancer Agency, Vancouver Cancer Centre, Vancouver, Canada
| | - A. Gennari
- Department of Medical Oncology, Galliera Hospital, Genoa, Italy
| | - N. Harbeck
- Brustzentrum der Universitat München, Munich, Germany
| | - C. Hudis
- Breast Medicine Service, Memorial Sloan-Kettering Cancer Centre, New York, USA
| | - B. Kaufman
- Sheba Medical Center, Tel Hashomer, Israel
| | - I. Krop
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston
| | - M. Mayer
- Advanced Breast Cancer.org, New York, USA
| | - H. Meijer
- Department of Radiation Oncology, Radvoud University Medical Center, Nijmegen, The Netherlands
| | - S. Mertz
- Metastatic Breast Cancer Network US, Inversness, USA
| | - S. Ohno
- Breast Oncology Centre, Cancer Institute Hospital, Tokyo, Japan
| | - O. Pagani
- Oncology Institute of Southern Switzerland and Breast Unit of Southern Switzerland, Bellinzona, Switzerland
| | | | - F. Peccatori
- European School of Oncology, Milan, Italy and Bellinzona, Switzerland
| | - F. Penault-Llorca
- Jean Perrin Centre, Comprehensive Cancer Centre, Clermont Ferrand, France
| | - M. J. Piccart
- Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - J. Y. Pierga
- Department of Medical Oncology, Institut Curie-Université Paris Descartes, Paris, France
| | - H. Rugo
- Department of Medicine, Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
| | - L. Shockney
- Department of Surgery and Oncology, Johns Hopkins Breast Center, Baltimore
| | - G. Sledge
- Indiana University Medical CTR, Indianapolis
| | - S. Swain
- Lombardi Comprehensive Cancer Center, Georgetown University, Washington, USA
| | - C. Thomssen
- Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle an der Saale, Germany
| | - A. Tutt
- Breakthrough Breast Cancer Research Unit, King’s College London and Guy’s and St Thomas’s NHS Foundation Trust, London, UK
| | - D. Vorobiof
- Sandton Oncology Centre, Johannesburg, South Africa
| | - B. Xu
- Department of Medical Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| | - L. Norton
- Breast Cancer Program, Memorial Sloan-Kettering Cancer Centre, New York
| | - E. Winer
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
| |
Collapse
|
23
|
Damaraju S, Gorbunova V, Gelmon K, García-Saenz J, Morales-Murillo S, AbiGerges D, Canon JL, Kiselev I, Cohen GL, Jerusalem G, Thireau F, Fresco R, Houé V, Press MF, Kumaran M, Mackey JR. Abstract P1-13-03: Genome wide association study (GWAS) of genetic variants associated with docetaxel toxicity in the ROSE/TRIO-012 trial. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p1-13-03] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Genetic predisposition to docetaxel (Doc) toxicity contributes to unacceptable toxicity and reduced dose intensity, and may influence disease outcomes. We previously reported variants associated with Doc toxicity in candidate gene single nucleotide polymorphism (SNP) associations in a breast cancer treatment setting (Damaraju et al. Eur J Cancer (suppl); Vol 8 (7), page 175, 2010) and the identified variants were confirmed in an independent validation study (Damaraju et al, J Clin Oncol Vol 33, Issue 15 suppl, 2015: 540). Others have reported candidate SNP (Breast Cancer Res Treat, 2011 SWOG 0221 study) and GWAS (Clin Cancer Res 2012 CALGB 40101 study) identified variants associated with paclitaxel mediated peripheral neuropathy. However, the overlap on the variants identified thus far between Doc and paclitaxel are limited, prompting a genome wide search to find variants contributing to Doc specific toxicity.
Methods: TRIO-012 is a double blinded, multinational trial that randomized 1,144 patients with advanced breast cancer to receive first-line Doc in combination with ramucirumab (RAM) or placebo (Mackey et al. J Clin Oncol Jan 10, 2015:141-148). Study subjects (n=719) in the Doc+RAM or Doc+placebo arm with available germline DNA are being genotyped; all subjects provided ethics-committee approved prospective consent for this genetic study. Genotyping are being performed with Affymetrix SNP 6.0 arrays. Genotype data will be filtered for deviations from Hardy Weinberg Equilibrium and minor allele frequency of >0.05. Doc-induced adverse events (AEs) are based on CTCAE (Common Terminology Criteria for Adverse Events v4.1) toxicity grades. Toxicities >2 scored for fatigue (n=96), myalgia (n=22), peripheral neuropathy (n=17) will be analysed as individual phenotypes in comparison with the no toxicity group (toxicity grades 0-1) and in a combined analysis of all Doc induced toxicities (0-1, n=599 vs. >2, n=120). Dominant genotypic model is assumed; Chi-square test, FDR and/or 10000 permutations were employed using SVS v8.3 and p<0.05 considered statistically significant. We will identify population stratification using EIGENSTRAT method and will correct the association statistics using the Eigenvectors along with age and BMI as covariates. Fine mapping of the identified loci will be attempted using imputation tools. We will interrogate the data for cumulative dose to toxicity and correlate SNPs identified with survival outcomes.
Results and conclusions: We expect to reconfirm the associations of loci reported in candidate SNP and previous GWAS studies; XKR4 (rs4737264) for peripheral neuropathy, CYP3A5*3 (rs776746) with fatigue, and FACND2 (rs7637888) with myalgia in addition to the potential novel variants distinct from paclitaxel AE GWAS studies. Fine mapping around these loci may help identify potential causal variants. Both candidate SNP and GWAS identified variants may aid in developing risk stratification models. The GWAS identified loci and the flanking genes will be interrogated using the ingenuity pathway analysis for insights in to the biological roles in the drug metabolism. We expect to complete the analysis by mid-November 2015.
Citation Format: Damaraju S, Gorbunova V, Gelmon K, García-Saenz J, Morales-Murillo S, AbiGerges D, Canon J-L, Kiselev I, Cohen GL, Jerusalem G, Thireau F, Fresco R, Houé V, Press MF, Kumaran M, Mackey JR. Genome wide association study (GWAS) of genetic variants associated with docetaxel toxicity in the ROSE/TRIO-012 trial. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-13-03.
Collapse
Affiliation(s)
- S Damaraju
- Cross Cancer Institute; University of Alberta, Edmonton, AB, Canada; N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russian Federation; British Columbia Cancer Agency, Vancouver, Canada; Hospital Clinico Universitario San Carlos, Madrid, Spain; Hospital Universitario Arnau de Vilanova, Lleida, Spain; Middle East Institute of Health, Bsalim, Lebanon; Grand Hôpital de Charleroi, Charleroi, Belgium; Kursk Regional Oncology Dispensary, Kursk, Russian Federation; Mary Potter Oncology Center, Pretoria, South Africa; Centre Hospitalier Universitaire du Sart-Tilman, Liege, Belgium; Translational Reserach in Oncology (TRIO), Paris, France; Translational Reserach in Oncology (TRIO), Montevideo, Uruguay; University of Southern California, Los Angeles, CA
| | - V Gorbunova
- Cross Cancer Institute; University of Alberta, Edmonton, AB, Canada; N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russian Federation; British Columbia Cancer Agency, Vancouver, Canada; Hospital Clinico Universitario San Carlos, Madrid, Spain; Hospital Universitario Arnau de Vilanova, Lleida, Spain; Middle East Institute of Health, Bsalim, Lebanon; Grand Hôpital de Charleroi, Charleroi, Belgium; Kursk Regional Oncology Dispensary, Kursk, Russian Federation; Mary Potter Oncology Center, Pretoria, South Africa; Centre Hospitalier Universitaire du Sart-Tilman, Liege, Belgium; Translational Reserach in Oncology (TRIO), Paris, France; Translational Reserach in Oncology (TRIO), Montevideo, Uruguay; University of Southern California, Los Angeles, CA
| | - K Gelmon
- Cross Cancer Institute; University of Alberta, Edmonton, AB, Canada; N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russian Federation; British Columbia Cancer Agency, Vancouver, Canada; Hospital Clinico Universitario San Carlos, Madrid, Spain; Hospital Universitario Arnau de Vilanova, Lleida, Spain; Middle East Institute of Health, Bsalim, Lebanon; Grand Hôpital de Charleroi, Charleroi, Belgium; Kursk Regional Oncology Dispensary, Kursk, Russian Federation; Mary Potter Oncology Center, Pretoria, South Africa; Centre Hospitalier Universitaire du Sart-Tilman, Liege, Belgium; Translational Reserach in Oncology (TRIO), Paris, France; Translational Reserach in Oncology (TRIO), Montevideo, Uruguay; University of Southern California, Los Angeles, CA
| | - J García-Saenz
- Cross Cancer Institute; University of Alberta, Edmonton, AB, Canada; N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russian Federation; British Columbia Cancer Agency, Vancouver, Canada; Hospital Clinico Universitario San Carlos, Madrid, Spain; Hospital Universitario Arnau de Vilanova, Lleida, Spain; Middle East Institute of Health, Bsalim, Lebanon; Grand Hôpital de Charleroi, Charleroi, Belgium; Kursk Regional Oncology Dispensary, Kursk, Russian Federation; Mary Potter Oncology Center, Pretoria, South Africa; Centre Hospitalier Universitaire du Sart-Tilman, Liege, Belgium; Translational Reserach in Oncology (TRIO), Paris, France; Translational Reserach in Oncology (TRIO), Montevideo, Uruguay; University of Southern California, Los Angeles, CA
| | - S Morales-Murillo
- Cross Cancer Institute; University of Alberta, Edmonton, AB, Canada; N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russian Federation; British Columbia Cancer Agency, Vancouver, Canada; Hospital Clinico Universitario San Carlos, Madrid, Spain; Hospital Universitario Arnau de Vilanova, Lleida, Spain; Middle East Institute of Health, Bsalim, Lebanon; Grand Hôpital de Charleroi, Charleroi, Belgium; Kursk Regional Oncology Dispensary, Kursk, Russian Federation; Mary Potter Oncology Center, Pretoria, South Africa; Centre Hospitalier Universitaire du Sart-Tilman, Liege, Belgium; Translational Reserach in Oncology (TRIO), Paris, France; Translational Reserach in Oncology (TRIO), Montevideo, Uruguay; University of Southern California, Los Angeles, CA
| | - D AbiGerges
- Cross Cancer Institute; University of Alberta, Edmonton, AB, Canada; N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russian Federation; British Columbia Cancer Agency, Vancouver, Canada; Hospital Clinico Universitario San Carlos, Madrid, Spain; Hospital Universitario Arnau de Vilanova, Lleida, Spain; Middle East Institute of Health, Bsalim, Lebanon; Grand Hôpital de Charleroi, Charleroi, Belgium; Kursk Regional Oncology Dispensary, Kursk, Russian Federation; Mary Potter Oncology Center, Pretoria, South Africa; Centre Hospitalier Universitaire du Sart-Tilman, Liege, Belgium; Translational Reserach in Oncology (TRIO), Paris, France; Translational Reserach in Oncology (TRIO), Montevideo, Uruguay; University of Southern California, Los Angeles, CA
| | - J-L Canon
- Cross Cancer Institute; University of Alberta, Edmonton, AB, Canada; N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russian Federation; British Columbia Cancer Agency, Vancouver, Canada; Hospital Clinico Universitario San Carlos, Madrid, Spain; Hospital Universitario Arnau de Vilanova, Lleida, Spain; Middle East Institute of Health, Bsalim, Lebanon; Grand Hôpital de Charleroi, Charleroi, Belgium; Kursk Regional Oncology Dispensary, Kursk, Russian Federation; Mary Potter Oncology Center, Pretoria, South Africa; Centre Hospitalier Universitaire du Sart-Tilman, Liege, Belgium; Translational Reserach in Oncology (TRIO), Paris, France; Translational Reserach in Oncology (TRIO), Montevideo, Uruguay; University of Southern California, Los Angeles, CA
| | - I Kiselev
- Cross Cancer Institute; University of Alberta, Edmonton, AB, Canada; N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russian Federation; British Columbia Cancer Agency, Vancouver, Canada; Hospital Clinico Universitario San Carlos, Madrid, Spain; Hospital Universitario Arnau de Vilanova, Lleida, Spain; Middle East Institute of Health, Bsalim, Lebanon; Grand Hôpital de Charleroi, Charleroi, Belgium; Kursk Regional Oncology Dispensary, Kursk, Russian Federation; Mary Potter Oncology Center, Pretoria, South Africa; Centre Hospitalier Universitaire du Sart-Tilman, Liege, Belgium; Translational Reserach in Oncology (TRIO), Paris, France; Translational Reserach in Oncology (TRIO), Montevideo, Uruguay; University of Southern California, Los Angeles, CA
| | - GL Cohen
- Cross Cancer Institute; University of Alberta, Edmonton, AB, Canada; N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russian Federation; British Columbia Cancer Agency, Vancouver, Canada; Hospital Clinico Universitario San Carlos, Madrid, Spain; Hospital Universitario Arnau de Vilanova, Lleida, Spain; Middle East Institute of Health, Bsalim, Lebanon; Grand Hôpital de Charleroi, Charleroi, Belgium; Kursk Regional Oncology Dispensary, Kursk, Russian Federation; Mary Potter Oncology Center, Pretoria, South Africa; Centre Hospitalier Universitaire du Sart-Tilman, Liege, Belgium; Translational Reserach in Oncology (TRIO), Paris, France; Translational Reserach in Oncology (TRIO), Montevideo, Uruguay; University of Southern California, Los Angeles, CA
| | - G Jerusalem
- Cross Cancer Institute; University of Alberta, Edmonton, AB, Canada; N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russian Federation; British Columbia Cancer Agency, Vancouver, Canada; Hospital Clinico Universitario San Carlos, Madrid, Spain; Hospital Universitario Arnau de Vilanova, Lleida, Spain; Middle East Institute of Health, Bsalim, Lebanon; Grand Hôpital de Charleroi, Charleroi, Belgium; Kursk Regional Oncology Dispensary, Kursk, Russian Federation; Mary Potter Oncology Center, Pretoria, South Africa; Centre Hospitalier Universitaire du Sart-Tilman, Liege, Belgium; Translational Reserach in Oncology (TRIO), Paris, France; Translational Reserach in Oncology (TRIO), Montevideo, Uruguay; University of Southern California, Los Angeles, CA
| | - F Thireau
- Cross Cancer Institute; University of Alberta, Edmonton, AB, Canada; N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russian Federation; British Columbia Cancer Agency, Vancouver, Canada; Hospital Clinico Universitario San Carlos, Madrid, Spain; Hospital Universitario Arnau de Vilanova, Lleida, Spain; Middle East Institute of Health, Bsalim, Lebanon; Grand Hôpital de Charleroi, Charleroi, Belgium; Kursk Regional Oncology Dispensary, Kursk, Russian Federation; Mary Potter Oncology Center, Pretoria, South Africa; Centre Hospitalier Universitaire du Sart-Tilman, Liege, Belgium; Translational Reserach in Oncology (TRIO), Paris, France; Translational Reserach in Oncology (TRIO), Montevideo, Uruguay; University of Southern California, Los Angeles, CA
| | - R Fresco
- Cross Cancer Institute; University of Alberta, Edmonton, AB, Canada; N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russian Federation; British Columbia Cancer Agency, Vancouver, Canada; Hospital Clinico Universitario San Carlos, Madrid, Spain; Hospital Universitario Arnau de Vilanova, Lleida, Spain; Middle East Institute of Health, Bsalim, Lebanon; Grand Hôpital de Charleroi, Charleroi, Belgium; Kursk Regional Oncology Dispensary, Kursk, Russian Federation; Mary Potter Oncology Center, Pretoria, South Africa; Centre Hospitalier Universitaire du Sart-Tilman, Liege, Belgium; Translational Reserach in Oncology (TRIO), Paris, France; Translational Reserach in Oncology (TRIO), Montevideo, Uruguay; University of Southern California, Los Angeles, CA
| | - V Houé
- Cross Cancer Institute; University of Alberta, Edmonton, AB, Canada; N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russian Federation; British Columbia Cancer Agency, Vancouver, Canada; Hospital Clinico Universitario San Carlos, Madrid, Spain; Hospital Universitario Arnau de Vilanova, Lleida, Spain; Middle East Institute of Health, Bsalim, Lebanon; Grand Hôpital de Charleroi, Charleroi, Belgium; Kursk Regional Oncology Dispensary, Kursk, Russian Federation; Mary Potter Oncology Center, Pretoria, South Africa; Centre Hospitalier Universitaire du Sart-Tilman, Liege, Belgium; Translational Reserach in Oncology (TRIO), Paris, France; Translational Reserach in Oncology (TRIO), Montevideo, Uruguay; University of Southern California, Los Angeles, CA
| | - MF Press
- Cross Cancer Institute; University of Alberta, Edmonton, AB, Canada; N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russian Federation; British Columbia Cancer Agency, Vancouver, Canada; Hospital Clinico Universitario San Carlos, Madrid, Spain; Hospital Universitario Arnau de Vilanova, Lleida, Spain; Middle East Institute of Health, Bsalim, Lebanon; Grand Hôpital de Charleroi, Charleroi, Belgium; Kursk Regional Oncology Dispensary, Kursk, Russian Federation; Mary Potter Oncology Center, Pretoria, South Africa; Centre Hospitalier Universitaire du Sart-Tilman, Liege, Belgium; Translational Reserach in Oncology (TRIO), Paris, France; Translational Reserach in Oncology (TRIO), Montevideo, Uruguay; University of Southern California, Los Angeles, CA
| | - M Kumaran
- Cross Cancer Institute; University of Alberta, Edmonton, AB, Canada; N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russian Federation; British Columbia Cancer Agency, Vancouver, Canada; Hospital Clinico Universitario San Carlos, Madrid, Spain; Hospital Universitario Arnau de Vilanova, Lleida, Spain; Middle East Institute of Health, Bsalim, Lebanon; Grand Hôpital de Charleroi, Charleroi, Belgium; Kursk Regional Oncology Dispensary, Kursk, Russian Federation; Mary Potter Oncology Center, Pretoria, South Africa; Centre Hospitalier Universitaire du Sart-Tilman, Liege, Belgium; Translational Reserach in Oncology (TRIO), Paris, France; Translational Reserach in Oncology (TRIO), Montevideo, Uruguay; University of Southern California, Los Angeles, CA
| | - JR Mackey
- Cross Cancer Institute; University of Alberta, Edmonton, AB, Canada; N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russian Federation; British Columbia Cancer Agency, Vancouver, Canada; Hospital Clinico Universitario San Carlos, Madrid, Spain; Hospital Universitario Arnau de Vilanova, Lleida, Spain; Middle East Institute of Health, Bsalim, Lebanon; Grand Hôpital de Charleroi, Charleroi, Belgium; Kursk Regional Oncology Dispensary, Kursk, Russian Federation; Mary Potter Oncology Center, Pretoria, South Africa; Centre Hospitalier Universitaire du Sart-Tilman, Liege, Belgium; Translational Reserach in Oncology (TRIO), Paris, France; Translational Reserach in Oncology (TRIO), Montevideo, Uruguay; University of Southern California, Los Angeles, CA
| |
Collapse
|
24
|
Lim H, Renouf D, Sun S, Ho C, Gelmon K, Chia S, Pleasance E, Jones M, Shen Y, Eirew P, Rassekh S, Deyell R, Yip S, Huntsman D, Roscoe R, Fok A, Ma Y, Jones S. 231 Whole genome analysis in a population-based cancer system: Results from sequencing >100 metastatic cancer patients. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30118-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
25
|
Baxter E, Gondara L, Lohrisch C, Chia S, Gelmon K, Hayes M, Davidson A, Tyldesley S. Using proliferative markers and Oncotype DX in therapeutic decision-making for breast cancer: the B.C. experience. ACTA ACUST UNITED AC 2015; 22:192-8. [PMID: 26089718 DOI: 10.3747/co.22.2284] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
BACKGROUND Proliferative scoring of breast tumours can guide treatment recommendations, particularly for estrogen receptor (er)-positive, her2-negative, T1-2, N0 disease. Our objectives were to □ estimate the proportion of such patients for whom proliferative indices [mitotic count (mc), Ki-67 immunostain, and Oncotype dx (Genomic Health, Redwood City, CA, U.S.A.) recurrence score (rs)] were obtained.□ compare the indices preferred by oncologists with the indices available to them.□ correlate Nottingham grade (ng) and its subcomponents with Oncotype dx.□ assess interobserver variation. METHODS All of the er-positive, her2-negative, T1-2, N0 breast cancers diagnosed from 2007 to 2011 (n = 5110) were linked to a dataset of all provincial breast cancers with a rs. A 5% random sample of the 5110 cancers was reviewed to estimate the proportion that had a mc, Ki-67 index, and rs. Correlation coefficients were calculated for the rs with ng subcomponent scores. Interobserver variation in histologic grading between outside and central review pathology reports was assessed using a weighted kappa test. RESULTS During 2007-2011, most cancers were histologically graded and assigned a mc; few had a Ki-67 index or rs. The ng and mc were significantly positively correlated with rs. The level of agreement in histologic scoring between outside and central pathology reports was good or very good. Very few cases with a low mc had a high rs (1.8%). CONCLUSIONS Patients with low ng and mc scores are unlikely to have a high rs, and thus are less likely to benefit from chemotherapy. In the context of limited resources, that finding can guide clinicians about when a rs adds the most value.
Collapse
Affiliation(s)
- E Baxter
- Department of Radiation Oncology, BC Cancer Agency, Vancouver Centre, BC
| | - L Gondara
- Department of Cancer Surveillance and Outcomes, BC Cancer Agency, Vancouver Centre, BC
| | - C Lohrisch
- Department of Medical Oncology, BC Cancer Agency, Vancouver Centre, BC
| | - S Chia
- Department of Medical Oncology, BC Cancer Agency, Vancouver Centre, BC
| | - K Gelmon
- Department of Medical Oncology, BC Cancer Agency, Vancouver Centre, BC
| | - M Hayes
- Department of Pathology, BC Cancer Agency, Vancouver Centre, BC
| | - A Davidson
- Department of Medical Oncology, BC Cancer Agency, Vancouver Centre, BC
| | - S Tyldesley
- Department of Radiation Oncology, BC Cancer Agency, Vancouver Centre, BC
| |
Collapse
|
26
|
Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van't Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†. Ann Oncol 2014; 25:1871-1888. [PMID: 25234545 PMCID: PMC4176456 DOI: 10.1093/annonc/mdu385] [Citation(s) in RCA: 284] [Impact Index Per Article: 28.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2014] [Accepted: 08/11/2014] [Indexed: 12/23/2022] Open
Affiliation(s)
- F Cardoso
- European School of Oncology & Breast Unit, Champalimaud Cancer Center, Lisbon, Portugal.
| | - A Costa
- European School of Oncology, Milan, Italy; European School of Oncology, Bellinzona, Switzerland
| | - L Norton
- Breast Cancer Program, Memorial Sloan-Kettering Cancer Centre, New York, USA
| | - E Senkus
- Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
| | - M Aapro
- Division of Oncology, Institut Multidisciplinaire d'Oncologie, Genolier, Switzerland
| | - F André
- Department of Medical Oncology, Gustave-Roussy Institute, Villejuif, France
| | - C H Barrios
- Department of Medicine, PUCRS School of Medicine, Porto Alegre, Brazil
| | - J Bergh
- Department of Oncology/Radiumhemmet, Karolinska Institutet & Cancer Center Karolinska and Karolinska University Hospital, Stockholm, Sweden
| | - L Biganzoli
- Department of Medical Oncology, Sandro Pitigliani Oncology Centre, Prato, Italy
| | - K L Blackwell
- Breast Cancer Clinical Program, Duke Cancer Institute, Durham, USA
| | - M J Cardoso
- Breast Unit, Champalimaud Cancer Center, Lisbon, Portugal
| | - T Cufer
- University Clinic Golnik, Medical Faculty Ljubljana, Ljubljana, Slovenia
| | - N El Saghir
- NK Basile Cancer Institute Breast Center of Excellence, American University of Beirut Medical Center, Beirut, Lebanon
| | - L Fallowfield
- Brighton & Sussex Medical School, University of Sussex, Falmer, UK
| | - D Fenech
- Breast Care Support Group, Europa Donna Malta, Mtarfa, Malta
| | - P Francis
- Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - K Gelmon
- BC Cancer Agency, Vancouver, Canada
| | - S H Giordano
- Departments of Health Services Research and Breast Medical Oncology, UT MD Anderson Cancer Center, Houston, USA
| | - J Gligorov
- APHP Tenon, IUC-UPMC, Francilian Breast Intergroup, AROME, Paris, France
| | - A Goldhirsch
- Program of Breast Health, European Institute of Oncology, Milan, Italy
| | - N Harbeck
- Brustzentrum der Universität München, Munich, Denmark
| | - N Houssami
- Screening and Test Evaluation Program, School of Public Health, Sydney Medical School, University of Sydney, Sydney, Australia
| | - C Hudis
- Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - B Kaufman
- Sheba Medical Center, Tel Hashomer, Israel
| | - I Krop
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
| | | | - U N Lin
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
| | | | - S D Merjaver
- University of Michigan Medical School and School of Public Health, Ann Arbor, USA
| | - E B Nordström
- Europa Donna Sweden & Bröstcancerföreningarnas Riksorganisation, BRO, Sundbyberg, Sweden
| | - O Pagani
- Oncology Institute of Southern Switzerland and Breast Unit of Southern Switzerland, Bellinzona, Switzerland
| | - A Partridge
- Department Medical Oncology, Division of Women's Cancers, Dana-Farber Cancer Institute, Boston, USA
| | - F Penault-Llorca
- Jean Perrin Centre, Comprehensive Cancer Centre, Clermont Ferrand, France
| | - M J Piccart
- Department of Medicine, Institut Jules Bordet, Brussels, Belgium
| | - H Rugo
- Department of Medicine, Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
| | - G Sledge
- Indiana University Medical CTR, Indianapolis, USA
| | - C Thomssen
- Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle an der Saale, Germany
| | - L Van't Veer
- Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA
| | - D Vorobiof
- Sandton Oncology Centre, Johannesburg, South Africa
| | - C Vrieling
- Department of Radiotherapy, Clinique des Grangettes, Geneva, Switzerland
| | - N West
- Nursing Division, Health Board, Cardiff and Vale University, Cardiff, UK
| | - B Xu
- Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| | - E Winer
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
| |
Collapse
|
27
|
Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van't Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast 2014; 23:489-502. [PMID: 25244983 DOI: 10.1016/j.breast.2014.08.009] [Citation(s) in RCA: 194] [Impact Index Per Article: 19.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2014] [Accepted: 08/12/2014] [Indexed: 12/25/2022] Open
Affiliation(s)
- F Cardoso
- European School of Oncology & Breast Unit, Champalimaud Cancer Center, Lisbon, Portugal.
| | - A Costa
- European School of Oncology, Milan, Italy; European School of Oncology, Bellinzona, Switzerland
| | - L Norton
- Breast Cancer Program, Memorial Sloan-Kettering Cancer Centre, New York, USA
| | - E Senkus
- Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
| | - M Aapro
- Division of Oncology, Institut Multidisciplinaire d'Oncologie, Genolier, Switzerland
| | - F André
- Department of Medical Oncology, Gustave-Roussy Institute, Villejuif, France
| | - C H Barrios
- Department of Medicine, PUCRS School of Medicine, Porto Alegre, Brazil
| | - J Bergh
- Department of Oncology/Radiumhemmet, Karolinska Institutet & Cancer Center Karolinska and Karolinska University Hospital, Stockholm, Sweden
| | - L Biganzoli
- Department of Medical Oncology, Sandro Pitigliani Oncology Centre, Prato, Italy
| | - K L Blackwell
- Breast Cancer Clinical Program, Duke Cancer Institute, Durham, USA
| | - M J Cardoso
- Breast Unit, Champalimaud Cancer Center, Lisbon, Portugal
| | - T Cufer
- University Clinic Golnik, Medical Faculty Ljubljana, Ljubljana, Slovenia
| | - N El Saghir
- NK Basile Cancer Institute Breast Center of Excellence, American University of Beirut Medical Center, Beirut, Lebanon
| | - L Fallowfield
- Brighton & Sussex Medical School, University of Sussex, Falmer, UK
| | - D Fenech
- Breast Care Support Group, Europa Donna Malta, Mtarfa, Malta
| | - P Francis
- Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - K Gelmon
- BC Cancer Agency, Vancouver, Canada
| | - S H Giordano
- Departments of Health Services Research and Breast Medical Oncology, UT MD Anderson Cancer Center, Houston, USA
| | - J Gligorov
- APHP Tenon, IUC-UPMC, Francilian Breast Intergroup, Arome, Paris, France
| | - A Goldhirsch
- Program of Breast Health, European Institute of Oncology, Milan, Italy
| | - N Harbeck
- Brustzentrum der Universität München, Munich, DE, USA
| | - N Houssami
- Screening and Test Evaluation Program, School of Public Health, Sydney Medical School, University of Sydney, Sydney, Australia
| | - C Hudis
- Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - B Kaufman
- Sheba Medical Center, Tel Hashomer, Israel
| | - I Krop
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
| | | | - U N Lin
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
| | - M Mayer
- Advanced BC.org, New York, USA
| | - S D Merjaver
- University of Michigan Medical School and School of Public Health, Ann Arbor, USA
| | - E B Nordström
- Europa Donna Sweden & Bröstcancerföreningarnas Riksorganisation, BRO, Sundbyberg, Sweden
| | - O Pagani
- Oncology Institute of Southern Switzerland and Breast Unit of Southern Switzerland, Bellinzona, Switzerland
| | - A Partridge
- Department Medical Oncology, Division of Women's Cancers, Dana-Farber Cancer Institute, Boston, USA
| | - F Penault-Llorca
- Jean Perrin Centre, Comprehensive Cancer Centre, Clermont Ferrand, France
| | - M J Piccart
- Department of Medicine, Institut Jules Bordet, Brussels, Belgium
| | - H Rugo
- Department of Medicine, Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA
| | - G Sledge
- Indiana University Medical CTR, Indianapolis, USA
| | - C Thomssen
- Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle an der Saale, DE, Germany
| | - L Van't Veer
- Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA
| | - D Vorobiof
- Sandton Oncology Centre, Johannesburg, South Africa
| | - C Vrieling
- Department of Radiotherapy, Clinique des Grangettes, Geneva, Switzerland
| | - N West
- Nursing Division, Health Board, Cardiff and Vale University, Cardiff, UK
| | - B Xu
- Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| | - E Winer
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
| | | | | |
Collapse
|
28
|
Wilson S, Tyldesley S, Speers C, Bernstein V, Voduc D, Gelmon K, Chia S. Abstract P6-06-04: Breast cancer in young women: Have the prognostic and predictive implications of breast cancer subtypes changed over time? Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p6-06-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Breast cancer (BC) occurring in very young women has a worse prognosis compared to older women, and is the leading cause of cancer death in women aged < 40 years. Over the last decade BC management has evolved to incorporate increased understanding of BC subtypes and new therapeutic agents such as taxanes and trastuzumab. Whether the previously observed poor prognosis associated with BC in young women persists in the context of modern adjuvant therapies and relative to the BC subtypes has not been widely investigated.
Methods:
We analyzed BC outcomes of young (40-49 years) and very young (<40 years) patients (pts) according to subtype defined by immune histochemistry (IHC) and evaluated for any changes over time by comparing 2 cohorts representative of different time periods. Data from 1,101 women aged < 50 diagnosed with invasive BC between 1986-1992, and 1,945 women diagnosed between 2004-2007 were abstracted from the British Columbia Cancer Agency's Breast Cancer Outcomes Database and analyzed according to two age categories (40 years and 40-49 years) and subtype (IHC was available on the earlier cohort from an established tumor repository for those years). Subtypes were defined as follows: Luminal: estrogen receptor (ER) and/or progesterone receptor (PR) positive, and HER2 negative, HER2: HER2 positive and any ER/PR, and Triple Negative (TN) (ie for ER,PR and HER2 negative). Survival analysis was performed using the Kaplan Meier method.
Results:
Median follow-up was 13.2 years and 6.2 years for the 1986-1992 and 2004-2007 cohorts respectively. Within both time cohorts, luminal subtype pts <40 demonstrated worse survival compared with those 40-49. This difference remained after accounting for grade in the contemporary cohort alone (Hazard ratio 0.50 p = 0.0001). Inferior survival was observed for pts <40 with HER2 BC in the 1986-1992 cohort, no impact of age was demonstrated in the HER2 2004-2007 cohort. No survival difference was seen between the age groups for TN BC in either time cohort. Across the HER2 and TN subtypes, and for luminal pts 40-49 a significant improvement was seen in 5-year RFS and OS between the 2 time cohorts. 5-year RFS but not OS improved over time for the luminal pts <40.
5 year overall survival 1986-1992 2004-2007 5-yr OS (%) 5-yr OS (%) p value (95% CI) (95% CI) Luminalage < 4082 (76-89) 88 (84-93) 0.138 age 40-4990 (87-92) 95 (94-97) 0.001 p value0.055 <0.001 HER2age < 4049 (35-63) 89 (83-95) <0.001 age 40-4966 (57-75) 89 (83-94) <0.001 p value0.017 0.879 TNage < 40 (101)67 (58-77) 82 (73-90) 0.011 age 40-49 (182)74 (67-80) 84 (79-89) <0.001 p value0.909 0.759
Conclusions:
We observed a significant improvement in survival over time for both HER2 and TN BC which may reflect improvements in adjuvant strategies based on subtype presentation. Inferior survival for pts <40 with luminal BC persists in the modern era and this group should be targeted for research.
5 year relapse free survival 1986-1992 2004-2007 5-yr RFS (%) 5-yr RFS (%) p value (95% CI) (95% CI) Luminalage<4065(57-74) 79 (74-85) <0.001 age 40-4977 (72-80) 92 (91-94) <0.001 p value0.009 <0.001 HER2age<4039 (25-52) 81 (70-92) <0.001 age 40-4958 (48-67) 84 (80-88) <0.001 p value0.039 0.879 TNage<4060 (51-70) 78 (69-87) 0.014 age 40-4963 (56-70) 77 (71-82) 0.001 p value0.868 0.933
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P6-06-04.
Collapse
Affiliation(s)
- S Wilson
- British Columbia Cancer Agency, Vancouver, BC, Canada
| | - S Tyldesley
- British Columbia Cancer Agency, Vancouver, BC, Canada
| | - C Speers
- British Columbia Cancer Agency, Vancouver, BC, Canada
| | - V Bernstein
- British Columbia Cancer Agency, Vancouver, BC, Canada
| | - D Voduc
- British Columbia Cancer Agency, Vancouver, BC, Canada
| | - K Gelmon
- British Columbia Cancer Agency, Vancouver, BC, Canada
| | - S Chia
- British Columbia Cancer Agency, Vancouver, BC, Canada
| |
Collapse
|
29
|
Courneya KS, Segal RJ, McKenzie DC, Dong H, Gelmon K, Friedenreich CM, Yasui Y, Reid RD, Crawford JJ, Mackey JR. Abstract P4-08-01: Effects of exercise during adjuvant chemotherapy on clinical outcomes in early stage breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p4-08-01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Observational studies suggest that physical activity following a diagnosis of breast cancer may be associated with a lower risk of recurrence and death. Some studies also suggest possible effect modification by disease stage, body mass index, and receptor status. To date, however, there are no randomized trials examining the effects of exercise on disease outcomes in any cancer patient group. Here, we report an exploratory follow-up of disease outcomes from the Supervised Trial of Aerobic versus Resistance Training (START). Patients and Methods: The START Trial was a Canadian multicenter trial that randomized 242 breast cancer patients starting adjuvant chemotherapy to either usual care (n = 82) or supervised aerobic (n = 78) or resistance (n = 82) exercise for the duration of their chemotherapy. The primary efficacy endpoint for this exploratory analysis was disease-free survival (DFS). Secondary endpoints were overall survival (OS), distant disease-free survival (DDFS), and recurrence-free interval (RFI). The two exercise arms were combined for the analysis (n = 160) and selected subgroups were explored. Results: After a median follow-up of 89 months (IQR 81 to 96), there were 25/160 (15.6%) DFS events in the exercise groups and 18/82 (22.0%) in the control group (log-rank p = 0.21). Eight-year DFS was 82.7% for the exercise groups compared with 75.6% for the control group (Hazard ratio [HR] = 0.68, 95% CI = 0.37-1.24). There were 13/160 (8.1%) deaths in the exercise groups and 11/82 (13.4%) in the control group (log-rank p = 0.21). Eight-year OS was 91.2% in the exercise groups compared with 82.7% in the control group (HR = 0.60, 95% CI = 0.27 to 1.33. There were 20/160 (12.5%) DDFS events in the exercise groups and 16/82 (19.5%) in the control group (log-rank p = 0.15). Eight-year DDFS was 86.7% in the exercise groups compared with 78.3% in the control group (HR = 0.62, 95% CI = 0.32 to 1.19). Finally, there were 20/160 (12.5%) RFI events in the exercise groups and 17/82 (20.7%) in the control group (Gray's p = 0.095). Eight-year cumulative incidence of RFI was 12.6% in the exercise groups compared with 21.6% in the control group (HR = 0.58, 95% CI = 0.30 to 1.11). Subgroup analyses for DFS and RFI suggested stronger effects for women who were overweight/obese, had stage II/III cancer, receptor positive tumors, HER2 positive tumors, received taxane-based chemotherapies, and received at least 85% of their intended chemotherapy dose-intensity. The most notable subgroup effect was for patients who received optimal chemotherapy dosing with a borderline significant effect for DFS (HR = 0.50, 95% CI = 0.25 to 1.01) and a significant effect for RFI (HR = 0.38, 95% CI = 0.18 to 0.81). Conclusions: In this exploratory follow-up of the START Trial, there was a suggestion that exercise during adjuvant chemotherapy may improve several efficacy endpoints although none achieved statistical significance. Nevertheless, the magnitude of the effects appear to be meaningful with absolute 8-year survival differences between 7% and 9% and relative rate reductions between 30% and 40%. The START Trial provides the first randomized data to suggest that adding exercise to standard chemotherapy for breast cancer may improve outcomes. A definitive phase III trial is warranted.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-08-01.
Collapse
Affiliation(s)
- KS Courneya
- University of Alberta, Edmonton, AB, Canada; Ottawa Hospital Regional Cancer Center, Ottawa, ON, Canada; University of British Columbia, Vancouver, BC, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada; Alberta Health Services, Calgary, AB, Canada; University of Ottawa Heart Institute, Ottawa, ON, Canada; Cross Cancer Institute, Edmonton, AB, Canada
| | - RJ Segal
- University of Alberta, Edmonton, AB, Canada; Ottawa Hospital Regional Cancer Center, Ottawa, ON, Canada; University of British Columbia, Vancouver, BC, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada; Alberta Health Services, Calgary, AB, Canada; University of Ottawa Heart Institute, Ottawa, ON, Canada; Cross Cancer Institute, Edmonton, AB, Canada
| | - DC McKenzie
- University of Alberta, Edmonton, AB, Canada; Ottawa Hospital Regional Cancer Center, Ottawa, ON, Canada; University of British Columbia, Vancouver, BC, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada; Alberta Health Services, Calgary, AB, Canada; University of Ottawa Heart Institute, Ottawa, ON, Canada; Cross Cancer Institute, Edmonton, AB, Canada
| | - H Dong
- University of Alberta, Edmonton, AB, Canada; Ottawa Hospital Regional Cancer Center, Ottawa, ON, Canada; University of British Columbia, Vancouver, BC, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada; Alberta Health Services, Calgary, AB, Canada; University of Ottawa Heart Institute, Ottawa, ON, Canada; Cross Cancer Institute, Edmonton, AB, Canada
| | - K Gelmon
- University of Alberta, Edmonton, AB, Canada; Ottawa Hospital Regional Cancer Center, Ottawa, ON, Canada; University of British Columbia, Vancouver, BC, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada; Alberta Health Services, Calgary, AB, Canada; University of Ottawa Heart Institute, Ottawa, ON, Canada; Cross Cancer Institute, Edmonton, AB, Canada
| | - CM Friedenreich
- University of Alberta, Edmonton, AB, Canada; Ottawa Hospital Regional Cancer Center, Ottawa, ON, Canada; University of British Columbia, Vancouver, BC, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada; Alberta Health Services, Calgary, AB, Canada; University of Ottawa Heart Institute, Ottawa, ON, Canada; Cross Cancer Institute, Edmonton, AB, Canada
| | - Y Yasui
- University of Alberta, Edmonton, AB, Canada; Ottawa Hospital Regional Cancer Center, Ottawa, ON, Canada; University of British Columbia, Vancouver, BC, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada; Alberta Health Services, Calgary, AB, Canada; University of Ottawa Heart Institute, Ottawa, ON, Canada; Cross Cancer Institute, Edmonton, AB, Canada
| | - RD Reid
- University of Alberta, Edmonton, AB, Canada; Ottawa Hospital Regional Cancer Center, Ottawa, ON, Canada; University of British Columbia, Vancouver, BC, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada; Alberta Health Services, Calgary, AB, Canada; University of Ottawa Heart Institute, Ottawa, ON, Canada; Cross Cancer Institute, Edmonton, AB, Canada
| | - JJ Crawford
- University of Alberta, Edmonton, AB, Canada; Ottawa Hospital Regional Cancer Center, Ottawa, ON, Canada; University of British Columbia, Vancouver, BC, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada; Alberta Health Services, Calgary, AB, Canada; University of Ottawa Heart Institute, Ottawa, ON, Canada; Cross Cancer Institute, Edmonton, AB, Canada
| | - JR Mackey
- University of Alberta, Edmonton, AB, Canada; Ottawa Hospital Regional Cancer Center, Ottawa, ON, Canada; University of British Columbia, Vancouver, BC, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada; Alberta Health Services, Calgary, AB, Canada; University of Ottawa Heart Institute, Ottawa, ON, Canada; Cross Cancer Institute, Edmonton, AB, Canada
| |
Collapse
|
30
|
Voduc D, Cheang MCU, Tyldesley S, Chia S, Gelmon K, Speers C, Nielsen TO. Abstract P4-16-02: A survival benefit from locoregional radiotherapy for node-positive and CMF treated breast cancer is most significant in Luminal A tumors. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p4-16-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Between 1978–1986, 318 premenopausal women treated with mastectomy for lymph node positive breast cancer, were randomized to CMF chemotherapy alone vs. CMF chemotherapy and adjuvant radiotherapy (RT) to the chest wall and regional lymph nodes. After 15 years of follow-up, post-mastectomy RT was associated with a statistically significant 29% relative risk reduction in mortality. Recent evidence suggests that Luminal A tumors, identified using hormone receptors and Ki67, have a particularly favorable prognosis. We retrospectively identified the Luminal A tumors from this clinical trial cohort to determine if the response to postmastectomy RT differed among Luminal A and non-Luminal A tumors.
Methods: 203 archival breast tumor samples from this study were used to construct a tissue microarray. Luminal A tumors were identified using an immunopanel consisting of: estrogen receptor, progestorone receptor, Her2, and Ki67. Luminal A tumors were defined as either ER or PR positive, Her2 negative, and Ki67 < 14%. Kaplan-Meier estimates and the log-rank test were used to test the differences in locoregional relapse free survival (LRFS) and breast cancer specific survival (BCSS). Interaction between treatment and Luminal A/Non-luminal A were tested using Cox regression analysis.
Results: The intrinsic subtype was successfully determined in 144 breast tumors, and 49 were classified as Luminal A (34%). Survival outcomes at 10 years are summarized in Table 1:
Conclusion: Our study examines the outcome of Luminal A tumors in patients with higher risk (premenopausal and lymph node positive) breast cancer treated with CMF chemotherapy. We observed that both subjects with Luminal A tumors and non-Luminal A tumors appear to demonstrate improved locoregional control with post-mastectomy RT, although this was only significant for Luminal A tumors. The non-significant interaction test suggests that there is no observable difference in radiosensitivity in this limited study population. However, the improvement in BCSS with post-mastectomy RT was only significant in the subjects with Luminal A tumors, and the interaction test was statistically significant.
Our results raise the possibility that patients with non-Luminal A breast tumors are at higher risk of occult metastatic disease at presentation, and may not derive a survival benefit with improved locoregional control in the setting of CMF chemotherapy. In contrast, locoregional control has a significant effect on survival with Luminal A tumors. Our study suggests that a favorable Luminal A diagnosis should not be a reason to omit regional radiotherapy in node positive patients, as it is this subgroup that may derive the greatest benefit.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P4-16-02.
Collapse
Affiliation(s)
- D Voduc
- BC Cancer Agency, Vancouver, BC, Canada; University of British Columbia, Vancouver, BC, Canada
| | - MCU Cheang
- BC Cancer Agency, Vancouver, BC, Canada; University of British Columbia, Vancouver, BC, Canada
| | - S Tyldesley
- BC Cancer Agency, Vancouver, BC, Canada; University of British Columbia, Vancouver, BC, Canada
| | - S Chia
- BC Cancer Agency, Vancouver, BC, Canada; University of British Columbia, Vancouver, BC, Canada
| | - K Gelmon
- BC Cancer Agency, Vancouver, BC, Canada; University of British Columbia, Vancouver, BC, Canada
| | - C Speers
- BC Cancer Agency, Vancouver, BC, Canada; University of British Columbia, Vancouver, BC, Canada
| | - TO Nielsen
- BC Cancer Agency, Vancouver, BC, Canada; University of British Columbia, Vancouver, BC, Canada
| |
Collapse
|
31
|
Abstract
BACKGROUND Triple-negative breast cancer (TNBC) is a distinct subset of breast cancer (BC) defined by the lack of immunohistochemical expression of the estrogen and progesterone receptors and human epidermal growth factor receptor 2. It is highly heterogeneous and displays overlapping characteristics with both basal-like and BC susceptibility gene 1 and 2 mutant BCs. This review evaluates the activity of emerging targeted agents in TNBC. DESIGN A systematic review of PubMed and conference databases was carried out to identify randomised clinical trials reporting outcomes in women with TNBC treated with targeted and platinum-based therapies. RESULTS AND DISCUSSION Our review identified TNBC studies of agents with different mechanisms of action, including induction of synthetic lethality and inhibition of angiogenesis, growth, and survival pathways. Combining targeted agents with chemotherapy in TNBC produced only modest gains in progression-free survival, and had little impact on survival. Six TNBC subgroups have been identified and found to differentially respond to specific targeted agents. The use of biological preselection to guide therapy will improve therapeutic indices in target-bearing populations. CONCLUSION Ongoing clinical trials of targeted agents in unselected TNBC populations have yet to produce substantial improvements in outcomes, and advancements will depend on their development in target-selected populations.
Collapse
Affiliation(s)
- K Gelmon
- Department of Medicine, University of British Columbia and; Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada.
| | - R Dent
- Medical Oncology, National Cancer Center Singapore and; Office of Clinical Sciences, Duke-NUS Graduate Medical School Singapore, Singapore
| | - J R Mackey
- Department of Oncology, University of Alberta and; Department of Medical Oncology, Cross Cancer Institute, Edmonton, Canada
| | - K Laing
- Department of Medicine, Memorial University and; Cancer Care Program, Eastern Health, St John's, Canada
| | - D McLeod
- Kaleidoscope Strategic, Toronto, Canada
| | - S Verma
- Department of Medicine, University of Toronto; Department of Medicine, Division of Medical Oncology/Hematology, Sunnybrook Health Sciences Centre, Toronto, Canada
| |
Collapse
|
32
|
Barrios C, Forbes JF, Jonat W, Conte P, Gradishar W, Buzdar A, Gelmon K, Gnant M, Bonneterre J, Toi M, Hudis C, Robertson JFR. The sequential use of endocrine treatment for advanced breast cancer: where are we? Ann Oncol 2012; 23:1378-86. [PMID: 22317766 PMCID: PMC6267865 DOI: 10.1093/annonc/mdr593] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2011] [Accepted: 11/23/2011] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Hormone receptor-positive advanced breast cancer is an increasing health burden. Although endocrine therapies are recognised as the most beneficial treatments for patients with hormone receptor-positive advanced breast cancer, the optimal sequence of these agents is currently undetermined. METHODS We reviewed the available data on randomised controlled trials (RCTs) of endocrine therapies in this treatment setting with particular focus on RCTs reported over the last 15 years that were designed based on power calculations on primary end points. RESULTS In this paper, data are reviewed in postmenopausal patients for the use of tamoxifen, aromatase inhibitors and fulvestrant. We also consider the available data on endocrine crossover studies and endocrine therapy in combination with chemotherapy or growth factor therapies. Treatment options for premenopausal patients and those with estrogen receptor-/human epidermal growth factor receptor 2-positive tumours are also evaluated. CONCLUSION We present the level of evidence available for each endocrine agent based on its efficacy in advanced breast cancer and a diagram of possible treatment pathways.
Collapse
Affiliation(s)
- C. Barrios
- Internal Medicine Department, PUCRS School of Medicine, Porto Alegre,
Brazil
| | - J. F. Forbes
- School of Medicine & Public Health, University of Newcastle, Newcastle,
Australia
| | - W. Jonat
- Department of Obstetrics and Gynaecology, University of Kiel, Kiel,
Germany
| | - P. Conte
- Department of Oncology and Hematology, University of Modena and Reggio
Emilia, Modena, Italy
| | - W. Gradishar
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Feinberg School of Medicine, Chicago
| | - A. Buzdar
- Department of Breast Medical Oncology, University of Texas MD Anderson
Cancer Center, Houston, USA
| | - K. Gelmon
- Department of Medical Oncology, University of British Columbia, Vancouver,
Canada
| | - M. Gnant
- Department of Surgery, Comprehensive Cancer Centre Vienna, Medical
University of Vienna, Vienna, Austria
| | - J. Bonneterre
- Integrated Clinical Research Unit, Centre Oscar Lambret, Lille, France
| | - M. Toi
- Breast Surgery Department, Kyoto University, Kyoto, Japan
| | - C. Hudis
- Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New
York, USA
| | - J. F. R. Robertson
- Faculty of Medicine and Health Sciences, Nottingham University, Derby,
UK
| |
Collapse
|
33
|
Prat A, Cheang M, Martín M, Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard P, Nielsen T, Perou C. 10O_PR Prognostic Significance of Progesterone Receptor-Positive Tumor Cells Within Immunohistochemically-Defined Luminal A Breast Cancer. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(19)65682-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
34
|
Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, Francis P, Gligorov J, Kyriakides S, Lin N, Pagani O, Senkus E, Thomssen C, Aapro M, Bergh J, Di Leo A, El Saghir N, Ganz PA, Gelmon K, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Leadbeater M, Mayer M, Rodger A, Rugo H, Sacchini V, Sledge G, van't Veer L, Viale G, Krop I, Winer E. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012; 21:242-52. [PMID: 22425534 DOI: 10.1016/j.breast.2012.03.003] [Citation(s) in RCA: 242] [Impact Index Per Article: 20.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
The 1st international Consensus Conference for Advanced Breast Cancer (ABC 1) took place on November 2011, in Lisbon. Consensus guidelines for the management of this disease were developed. This manuscript summarizes these international consensus guidelines.
Collapse
Affiliation(s)
- F Cardoso
- European School of Oncology & Breast Unit, Champalimaud Cancer Center, Lisbon, Portugal.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Hilton JF, Dong B, Bouganim N, Chapman JAW, Arnaout A, O'Malley F, Nielsen T, Gelmon K, Yerushalmi R, Levine M, Bramwell V, Whelan T, Pritchard KI, Shepherd L, Clemons M. P2-12-27: Simply Adding Together the Diameters of Tumor Foci in Patients with Multicentric or Multifocal Disease Does Not Add Any Additional Prognostic Information: An Analysis from NCIC CTG MA.12 Randomized Placebo-Controlled Trial of Tamoxifen after Adjuvant Chemotherapy in Pre-Menopausal Women with Early Breast Cancer. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p2-12-27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: A common clinical conundrum in breast cancer management is whether pathologic T stage in women with multicentric or multifocal disease should be taken as the diameter of the largest focus or as the sum of all foci in the breast. Most staging systems, such as the American Joint Committee on Cancer (AJCC), simply use the largest tumor focus for staging. We examine here the impact of alternate methods of estimating tumour size including measures of total tumor size, volume and surface area.
Materials & Methods: NCIC CTG MA.12 is a randomized placebo-controlled trial of tamoxifen after adjuvant chemotherapy for pre-menopausal women with early breast cancer. Median follow up is 9.7 years. Pathologically reported patient tumor dimensions for up to 3 foci were utilized to examine the effects of tumor size on Breast-Cancer-Free-Interval (BCFI), defined as the time from randomization until recurrence (defined as first local, regional, distant, or contralateral invasive tumor or DCIS). Tumor size was estimated as 1) pathologic T stage as per AJCC criteria; 2) largest dimension of largest tumor focus (cm); 3) sum of largest dimension(s) of tumor foci (cm); 4) sum of surface area(s) of tumor foci (cm2), and 5) sum of volume of tumor foci (cm3). Step-wise forward unstratified Cox regression was used to assess the different effects of tumor size. Results: This study accrued 672 patients, 43% with T1 tumors, 51% with T2 tumors, and 6% with T3/T4 tumors; 25% were node negative and 56% had 1–3 positive lymph nodes. 75% were locally determined to have hormone receptor positive tumors. A higher number of involved lymph nodes was associated with significantly shorter BCFI (p<0.0001). None of pathologic T stage (p=0.14), largest dimension of largest tumor size (p=0.14), sum of largest dimensions of tumor foci (p=0.24), sum of surface area (p=0.38), and sum of volume of foci (p=0.51) were significantly associated with BCFI. Likewise, lymphovascular invasion (p=0.08), grade (p=0.14), nor administration of anthracycline therapy (p=0.08) were associated with BCFI.
Discussion: In the MA.12 population of pre-menopausal women randomized to either tamoxifen or placebo, the sole factor significantly associated with BCFI was nodal status. No measure of tumor size in unifocal or multicentric/multifocal tumors impacted BCFI. The findings of this mature data set suggest that simply adding together the diameters of tumors in patients with multicentric or multifocal disease did not add any additional prognostic information.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-12-27.
Collapse
Affiliation(s)
- JF Hilton
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - B Dong
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - N Bouganim
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - J-AW Chapman
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - A Arnaout
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - F O'Malley
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - T Nielsen
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - K Gelmon
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - R Yerushalmi
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - M Levine
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - V Bramwell
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - T Whelan
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - KI Pritchard
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - L Shepherd
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - M Clemons
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| |
Collapse
|
36
|
Bouganim N, Dong B, Hilton JF, Chapman JAW, Arnaout A, O'Malley F, Nielsen T, Gelmon K, Yerushalmi R, Levine M, Bramwell V, Whelan T, Pritchard KI, Shepherd L, Clemons M. P2-12-23: How Should We Assess Tumour Size (T Stage) in Patients with Multicentric/Multifocal Breast Cancer? Results from the NCIC CTG MA.5 Randomized Trial of CEF vs. CMF in Pre-Menopausal Women with Node Positive Breast Cancer. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p2-12-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
A common clinical conundrum in breast cancer management is whether pathologic T stage in women with multicentric or multifocal disease should be taken as the diameter of the largest focus or as the sum of all foci in the breast. Most staging systems, such as the American Joint Committee on Cancer (AJCC), simply use the largest tumour focus for staging. We examine here the impact of alternate methods of estimating tumour size including measures of total tumour size, volume and surface area.
Methods: NCIC CTG MA.5 is a randomized trial of CEF versus CMF in pre-menopausal women with node positive breast cancer.
Median follow up is 10 years. Pathologically reported patient tumour dimensions for up to 3 foci were utilized to examine the effects of tumour size on Breast-Cancer-Free-Interval (BCFI). BCFI is defined as the time from randomization until recurrence: first local invasive or DCIS, regional, distant, contralateral invasive or DCIS. Tumour size was estimated as 1) pathologic T stage as per AJCC criteria; 2) largest dimension of largest tumour focus (cm); 3) sum of largest dimension(s) of tumour foci (cm); 4) sum of surface area(s) of tumour foci (cm2), and 5) sum of volume of tumour foci (cm3). Step-wise forward unstratified Cox regression was used to assess the different effects of tumour size.
Results: This study accrued 710 patients, 37% with T1 tumours, 52% with T2 tumours and 9% with T3 tumours; 61% had 1 to 3 positive lymph nodes. 59% hormone receptor positive. Higher pathologic T stage (p=0.001) and greater surface area (p=0.02) were associated with shorter BCFI, as was lymphovascular invasion (p=0.03), and # of lymph nodes involved (p<0.0001). Administration of anthracycline therapy led to significantly longer BCFI (0.003). The sum of largest tumour sizes (p=0.33) and sum of tumour volume (p=0.34) were not significantly associated with BCFI. Additionally, when the less complete locally reported tumour grade data were included, higher tumour grade was associated with shorter BCFI (p<0.0001).
Conclusions: Consideration of multicentric and multifocal disease was an important adjunct to standard pathologic tumour size as was estimation of tumour surface area in this chemotherapy trial of node positive premenopausal women. However, simply adding together the diameters of tumours in patients with multicentric or multifocal disease did not add any additional prognostic information in this high risk patient population.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-12-23.
Collapse
Affiliation(s)
- N Bouganim
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - B Dong
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - JF Hilton
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - J-AW Chapman
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - A Arnaout
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - F O'Malley
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - T Nielsen
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - K Gelmon
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - R Yerushalmi
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - M Levine
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - V Bramwell
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - T Whelan
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - KI Pritchard
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - L Shepherd
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - M Clemons
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| |
Collapse
|
37
|
Woods R, Yerushalmi R, Speers C, Tydesley S, Gelmon K. P5-14-17: Stage IV at Presentation – Are HER2 Positive Tumors Overrepresented? Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p5-14-17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: A minority of patients are diagnosed with Stage IV breast cancer at presentation. Recent studies (Dawood 2010) have suggested a better outcome for de novo vs. recurrent Stage IV but they did not account for the variation of molecular subtype. We questioned whether HER2 overexpressing tumors were over-represented in de novo Stage IV disease, and whether this impacted on survival compared to other subtypes. Further, if different subtypes are more likely to present with metastatic disease, then this factor may need to be considered when developing guidelines for staging. With such considerations in mind, the purpose of this study was to determine the breast cancer subtypes according to stage. The main hypothesis was that HER2 positive tumors would be more prevalent in stage IV presentations. Methods: Using the Breast Cancer Outcomes Unit database from the BC Cancer Agency (BCCA), patients referred to the BCCA with a new diagnosis of breast cancer between 2005 and 2010 were selected. Patients with a previous or synchronous contralateral breast cancer, male cases, and patients with referrals for reasons other than new disease were excluded. Four subtypes according to available markers were defined: ER+/HER2−, ER+/HER2+, ER-/HER2+, and ER-/HER2−.
Results: Using these criteria, 485 cases of de novo stage IV disease and 10,723 stages I — III cases were extracted. After excluding cases with missing data, our final cohort consisted of 10,186 stage I-III cases and 425 stage IV cases. Distribution by subtype is presented in the Table below.
Assessment of other patient characteristics for the group of Stage IV de novo patients revealed that age (younger for HER+ subgroups), site of metastases (more visceral vs. non- visceral for ER-/HER2+ and ER-/HER2−) and type of systemic therapy (chemotherapy (CT), hormone therapy (HT), trastuzumab (T) or not) were significant. Surgery rates for both mastectomy and breast-conserving surgery were similar for all subtypes. The ER-/HER2− subtype had the worst overall survival (p < 0.001).
Conclusion: Young age and HER2 overexpression is more common in stage IV de novo presentations (26.6% of stage IV tumors were HER2+ vs. only 16% of stage I-III tumors). This data may be important in considering routine staging guidelines at diagnosis to ensure correct diagnosis and treatment recommendations.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-14-17.
Collapse
Affiliation(s)
- R Woods
- 1BC Cancer Agency, Vancouver, BC, Canada
| | | | - C Speers
- 1BC Cancer Agency, Vancouver, BC, Canada
| | - S Tydesley
- 1BC Cancer Agency, Vancouver, BC, Canada
| | - K Gelmon
- 1BC Cancer Agency, Vancouver, BC, Canada
| |
Collapse
|
38
|
Gelmon K, Dent S, Chi K, Jonker D, Wainman N, Simpson R, Capier K, Chen E, Squires M, Seymour L. 512 NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)72219-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
39
|
Dawson SJ, Makretsov N, Blows FM, Driver KE, Provenzano E, Le Quesne J, Baglietto L, Severi G, Giles GG, McLean CA, Callagy G, Green AR, Ellis I, Gelmon K, Turashvili G, Leung S, Aparicio S, Huntsman D, Caldas C, Pharoah P. Erratum: BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer 2010. [PMCID: PMC2965882 DOI: 10.1038/sj.bjc.6605921] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
40
|
Dawson SJ, Makretsov N, Blows FM, Driver KE, Provenzano E, Le Quesne J, Baglietto L, Severi G, Giles GG, McLean CA, Callagy G, Green AR, Ellis I, Gelmon K, Turashvili G, Leung S, Aparicio S, Huntsman D, Caldas C, Pharoah P. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer 2010; 103:668-75. [PMID: 20664598 PMCID: PMC2938244 DOI: 10.1038/sj.bjc.6605736] [Citation(s) in RCA: 219] [Impact Index Per Article: 15.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2010] [Revised: 05/10/2010] [Accepted: 05/16/2010] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND Breast cancer is heterogeneous and the existing prognostic classifiers are limited in accuracy, leading to unnecessary treatment of numerous women. B-cell lymphoma 2 (BCL2), an antiapoptotic protein, has been proposed as a prognostic marker, but this effect is considered to relate to oestrogen receptor (ER) status. This study aimed to test the clinical validity of BCL2 as an independent prognostic marker. METHODS Five studies of 11 212 women with early-stage breast cancer were analysed. Individual patient data included tumour size, grade, lymph node status, endocrine therapy, chemotherapy and mortality. BCL2, ER, progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) levels were determined in all tumours. A Cox model incorporating the time-dependent effects of each variable was used to explore the prognostic significance of BCL2. RESULTS In univariate analysis, ER, PR and BCL2 positivity was associated with improved survival and HER2 positivity with inferior survival. For ER and PR this effect was time dependent, whereas for BCL2 and HER2 the effect persisted over time. In multivariate analysis, BCL2 positivity retained independent prognostic significance (hazard ratio (HR) 0.76, 95% confidence interval (CI) 0.66-0.88, P<0.001). BCL2 was a powerful prognostic marker in ER- (HR 0.63, 95% CI 0.54-0.74, P<0.001) and ER+ disease (HR 0.56, 95% CI 0.48-0.65, P<0.001), and in HER2- (HR 0.55, 95% CI 0.49-0.61, P<0.001) and HER2+ disease (HR 0.70, 95% CI 0.57-0.85, P<0.001), irrespective of the type of adjuvant therapy received. Addition of BCL2 to the Adjuvant! Online prognostic model, for a subset of cases with a 10-year follow-up, improved the survival prediction (P=0.0039). CONCLUSIONS BCL2 is an independent indicator of favourable prognosis for all types of early-stage breast cancer. This study establishes the rationale for introduction of BCL2 immunohistochemistry to improve prognostic stratification. Further work is now needed to ascertain the exact way to apply BCL2 testing for risk stratification and to standardise BCL2 immunohistochemistry for this application.
Collapse
Affiliation(s)
- S-J Dawson
- Department of Oncology, University of Cambridge, Cambridge CB1 9RN, UK
- Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 ORE, UK
| | - N Makretsov
- Department of Oncology, University of Cambridge, Cambridge CB1 9RN, UK
- Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 ORE, UK
| | - F M Blows
- Strangeways Research Laboratories, University of Cambridge, Cambridge CB1 9RN, UK
| | - K E Driver
- Strangeways Research Laboratories, University of Cambridge, Cambridge CB1 9RN, UK
| | - E Provenzano
- Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 ORE, UK
- Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust and NIHR Cambridge Biomedical Research Centre, Cambridge CB2 2QQ, UK
| | - J Le Quesne
- Department of Oncology, University of Cambridge, Cambridge CB1 9RN, UK
- Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 ORE, UK
| | - L Baglietto
- Cancer Epidemiology Centre, The Cancer Council Victoria, Carlton, Victoria 3053, Australia
- Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, University of Melbourne, Parkville, Victoria 3010, Australia
| | - G Severi
- Cancer Epidemiology Centre, The Cancer Council Victoria, Carlton, Victoria 3053, Australia
- Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, University of Melbourne, Parkville, Victoria 3010, Australia
| | - G G Giles
- Cancer Epidemiology Centre, The Cancer Council Victoria, Carlton, Victoria 3053, Australia
- Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, University of Melbourne, Parkville, Victoria 3010, Australia
| | - C A McLean
- Department of Anatomical Pathology, The Alfred Hospital, Melbourne, Victoria 3181, Australia
| | - G Callagy
- Department of Pathology, NUI, Galway, Ireland
| | - A R Green
- Department of Histopathology, Nottingham City Hospital, Nottingham NG5 1PB, UK
| | - I Ellis
- Department of Histopathology, Nottingham City Hospital, Nottingham NG5 1PB, UK
| | - K Gelmon
- Genetic Pathology Evaluation Centre of the Department of Pathology and Prostate Research Centre, Vancouver General Hospital, British Columbia Cancer Agency and University of British Columbia, Vancouver, British Columbia, Canada V6H 3Z6
| | - G Turashvili
- Genetic Pathology Evaluation Centre of the Department of Pathology and Prostate Research Centre, Vancouver General Hospital, British Columbia Cancer Agency and University of British Columbia, Vancouver, British Columbia, Canada V6H 3Z6
| | - S Leung
- Genetic Pathology Evaluation Centre of the Department of Pathology and Prostate Research Centre, Vancouver General Hospital, British Columbia Cancer Agency and University of British Columbia, Vancouver, British Columbia, Canada V6H 3Z6
| | - S Aparicio
- Genetic Pathology Evaluation Centre of the Department of Pathology and Prostate Research Centre, Vancouver General Hospital, British Columbia Cancer Agency and University of British Columbia, Vancouver, British Columbia, Canada V6H 3Z6
| | - D Huntsman
- Genetic Pathology Evaluation Centre of the Department of Pathology and Prostate Research Centre, Vancouver General Hospital, British Columbia Cancer Agency and University of British Columbia, Vancouver, British Columbia, Canada V6H 3Z6
| | - C Caldas
- Department of Oncology, University of Cambridge, Cambridge CB1 9RN, UK
- Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 ORE, UK
- Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust and NIHR Cambridge Biomedical Research Centre, Cambridge CB2 2QQ, UK
| | - P Pharoah
- Strangeways Research Laboratories, University of Cambridge, Cambridge CB1 9RN, UK
- Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust and NIHR Cambridge Biomedical Research Centre, Cambridge CB2 2QQ, UK
| |
Collapse
|
41
|
Chia S, Speers C, Gelmon K, Ellard S, Pickering R, O'Reilly S, Seal M. 7 Outcomes of women with early stage HER-2 over-expressing breast cancer receiving adjuvant trastuzumab: a population based analysis. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)70039-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
42
|
Yerushalmi R, Tyldsley S, Kennecke H, Speers C, Knight B, Gelmon K. Elevated Tumor Markers in the Different Breast Cancer Subtypes; Percentage and Correlation with Outcome. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-2125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Tumor markers (TMs) are widely used in breast cancer to monitor patients with metastatic disease during active treatment in conjunction with diagnostic imaging, history and physical examination. Studies of CA15-3 and CEA in metastatic disease have yielded positivity rates of approximately 80% and 40%, respectively. There is less information regarding CA-125 and breast carcinoma. Recently, there has been a renewed interest in tumor markers and their potential as therapeutic targets, including vaccine development, in various cancers. Early studies have reported an association between CA 15-3 levels and ER positivity. As far as we are aware, this is the first study to report elevated TM levels in the different breast subtypes and their correlation with outcome in each subtype. Aim: To document the rate of elevated tumor markers (CEA, CA15-3, CA-125) in the different subtypes and correlate TM with outcome. Methods: Women with breast cancer diagnosed between 1986 and 1992 and referred to the British Columbia Cancer Agency with M1 disease at presentation or who later developed a distant relapse were included. Archival paraffin tissue blocks were used to construct a tissue microarray. Breast cancer subtypes were defined as Luminal A (ER/PR+, HER2- and Ki67 <14%), Luminal B (ER/PR+ and HER2- and Ki67 ≥14%), Luminal HER2 (HER2+ and ER/PR+), HER2 (HER2+ and ER-and PR-), and Basal {HER2-, ER-PR- and (CK 5/6+ and/or EGFR+)} using immunohistochemical staining. In addition, we examined the triple negative (ER-, PR-, HER2-) non-basal subgroup. Levels of TM values (CA-15-3, CEA, CA-125) within 3 months of distant relapse date or anytime after were captured and percentage of elevated values (CA15-3>28, CEA>4, CA-125> 35) among the different subtypes were reported. Kaplan Meier (KM) plots were created for cases with elevated TM versus non-elevated TM cases. Results: 1,656 cases with distant metastases were potentially eligible for inclusion. Excluded cases: 428 cases without any linkage to TM data, 16 cases with subsequent contaralateral breast cancer (CBC) and no TM between the time of distant relapse and CBC, 127 cases with TM >3 months before distant relapse, and 187 cases where breast cancer subtype could not be determined. The percentage of TMs among the different breast cancer subtypes is shown in the table. Median duration of survival from time of diagnosis with metastatic disease was significantly shorter for patients with elevated TMs vs. those with normal TM values, p=0.003. Similar results were found when stratifying the results by subtype, with only Lum A and B attaining statistical significance, p=0.002 and p=0.016 respectively.Conclusion: Elevated TMs are documented in all breast cancer subtypes, with a significantly higher percentage of elevated TMs in luminal versus non-luminal groups. The lowest frequency of elevated TMs was documented in the non-basal TN cases. Elevated TMs in the metastatic setting predict worse outcome for Lum A/B subtypes.Table 1 : Percentage of elevated TMs among the different breast cancer subtypesSubtypeany TM %CA 15-3 %CEA %CA-125 %Lum A87816448Lum B88836054Lum Her2+86766339Her2+,ER-78705443Basal70642764Non Basal, Triple negative61582540p value<0.0010.001<0.0010.71
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 2125.
Collapse
|
43
|
Yerushalmi R, Woods R, Ravdin P, Speers C, Kennecke H, Gelmon K. Using Ki67 To Improve and Simplify Outcome Modeling for Breast Cancer. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-4042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Ki67 is a marker of proliferation which has several advantages over histological grade. Ki67 is determined less subjectively and is a continuous rather than a categorical variable. Many studies that have looked at Ki67 have been small and underpowered. A large population based tissue microarray was used to: A) test the prognostic value of Ki67 in testing and validation sets, and B) construct an improved model including Ki67 and conventional prognostic variables to predict patient outcome. Methods: The cohort included 2,780 patients with early breast cancer diagnosed in British Columbia and a median follow up of 14.5yrs. Variables included were: tumor size (T), number of positive nodes (N), grade, lymphovascular invasion (LVI), estrogen receptors (ER), progesterone receptors (PR), Her2, Ki67, local treatment (surgery, radiation) and systemic treatment (chemotherapy, hormonal). Prognostic factors were balanced between the training and validation sets. Prognostic variables were identified in the testing set among ER positive and ER negative cohorts using Cox Regression analysis and tested in the validation set. Results: The inclusion of Ki67 in the Cox Regression analysis resulted in the elimination of grade as a predictor. For ER positive disease independent predictors were T, N, LVI, PR, HER2, Ki67, local treatment, chemotherapy and hormonal therapy. Independent predictors among ER- cases were T, N, LVI, Ki-67, and chemotherapy. Predicted 10-yr Breast Cancer Specific Survival in the validation set was 72.0% versus 72.4% [SE: 1.2] observed. As subtle prognostic differences may result in very disparate treatment recommendations for Stage I breast cancers, we specifically reviewed this group. In analysis of stage I patients, there were no statistically significant deviations between predictions and observation; agreement between the predicted and observed 10-yr BCSS was excellent (86.0% vs 87.6% (SE: 1.6) p = 0.3169). As well, elevated Ki67 was common (53%) and was a powerful prognostic variable with causing more than a doubling of the 10-yr BrCa mortality (elevated ≥ 10% vs low < 10%, 16.8% vs 6.8%) in this group (table). Conclusion: In this study the proliferation marker Ki67 replaced histologic grade as a predictor of outcome for patients with early breast cancer. Predictive models such as Adjuvant! could incorporate Ki67 as an input variable and this modification is being developed. If models that use Ki67 are validated they may be able to be used globally and be cost effective compared to more expensive genomic predictors.Table: Predicted versus observed 10yr BCSS, based on the new modelPatientsSubgroupNPredicted SurvivalObserved Survivalp-valueAll patientsOverall139772.072.40.75 ER+101277.276.40.56 ER-38558.461.20.27 HER2+19755.658.00.50 HER2-120074.874.80.99Stage IOverall45386.087.60.32 ER+35287.690.40.09 ER-10179.678.40.77 HER2+4378.882.40.55 HER2-41086.888.40.33
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 4042.
Collapse
|
44
|
Baselga J, Cortes J, Fumoleau P, Petrella T, Gelmon K, Verma S, Pivot X, Ross G, Szado T, Gianni L. Pertuzumab and Trastuzumab: Re-Responses to 2 Biological Agents in Patients with HER2-Positive Breast Cancer Which Had Previously Progressed during Therapy with Each Agent Given Separately: A New Biological and Clinical Observation. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-5114] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Pertuzumab, a fully humanised IgG1 monoclonal antibody, is a human epidermal growth factor receptor 2 (HER2)-dimerisation inhibitor directed to the dimerisation epitope of HER2 (trastuzumab binds to the juxta-membrane epitope). Pertuzumab has demonstrated promising activity when given with trastuzumab to patients with HER2-positive metastatic breast cancer (mBC) which had progressed during therapy with trastuzumab in a 2-step Phase II study.1Methods: The protocol was amended to include a 3rd cohort of patients to determine the activity of pertuzumab when given without trastuzumab.2 Patients recruited into this 3rd cohort were allowed to have trastuzumab re-introduced in combination with pertuzumab if there was inadequate response to pertuzumab alone or response followed by relapse.Results: Twenty-nine patients were recruited into this 3rd cohort. Patients had reached their 3rd line of treatment for mBC. To date, 15 patients have had trastuzumab re-introduced after disease progression on trastuzumab therapy and pertuzumab monotherapy. Among these 15 patients, at the time of this analysis there have been 3 patients with confirmed responses. There are also 4 patients who had not yet undergone 8 cycles of assessments to reach the overall best response end point, of which at least 2 were experiencing stablisation of disease. Updated data on activity and toxicity will be presented.Conclusions: We believe this is the first time that anti-tumour activity has been reported in patients when 2 biological agents have been used together after the disease has progressed during therapy with each agent alone. There are several mechanisms which might explain this phenomenon. Trastuzumab prevents proteolytic cleavage of the extracellular domain of HER2, keeping the receptor in situ. The addition of a second antibody to a separate epitope increases the potential for antibody-dependent cell-mediated cytotoxicity and prevents dimerisation between HER2 and other HER family members, such as HER1 and HER3. The combined antibodies might increase the efficiency of inhibition of signal transduction. There are wide-ranging and potentially significant biological and clinical implications.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 5114.
Collapse
Affiliation(s)
- J. Baselga
- 1Vall d'Hebron University Hospital, Spain
| | - J. Cortes
- 1Vall d'Hebron University Hospital, Spain
| | | | | | - K. Gelmon
- 4British Columbia Cancer Agency, BC, Canada
| | - S. Verma
- 5Ottawa Regional Cancer Center, ON, Canada
| | | | - G. Ross
- 7Roche Products Limited, United Kingdom
| | - T. Szado
- 7Roche Products Limited, United Kingdom
| | | |
Collapse
|
45
|
Macfarlane RJ, Lohrisch C, Truong P, McKenzie D, Jespersen D, Nuraney S, Gaul K, Gelmon K, Kennecke H. Phase III randomized anastrozole exercise (RAE) trial: First planned interim analysis. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e20674] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e20674 Background: Adjuvant anastrozole (aA) is associated with arthralgias/myalgias (A/M), bone density loss, and hot flushes. Analgesics offer limited relief of musculoskeletal (MSK) symptoms and are associated with side effects of their own. The benefit of exercise on bone health, muscle strength, hot flushes, and quality of life (QOL) has been demonstrated; the objective of this trial is to determine if an exercise program improves anastrozole related A/M. Methods: This is a phase III, randomized trial of standard of care (observation) vs 48 weeks (wks) of exercise for women with BC on aA. Subjects in the control group receive literature about AIs (information on bone health, management of SEs of AIs). Subjects in the intervention group participate in a semi-supervised, individualized, and graduated 3x/wk exercise program (aerobic, resistance training, stretching) for 24 wks. From wks 25–48 independent exercise is recommended 3x/wk. The 10 endpoint is change in MSK symptoms as measured by 12 wk SF-36v2 bodily pain scores, NCI CTG toxicity, and visual analogue scale. 20 endpoints are QOL, hot flushes, bone density, and body mass. Physical activity and compliance with aA was monitored in both arms. The 1st interim analysis was planned after 10 patients were enrolled to evaluate accrual, compliance, and rate of discontinuation. Results: Accrual commenced December, 2007. Fourteen of a planned 72 patients have been enrolled (baseline data available for 13); 7 pts in the control arm (A) and 6 in the exercise arm (B). Median age was 59 (A) and 58 (B). Nine pts had baseline and 12 wk data available [5 (A), 4 (B)]. There were no withdrawals and compliance with scheduled exercise was 100%. Of the NCI CTG A/M deemed probably/definitely related to aA, there is no change in the number reported at baseline vs wk 12 in Arm A. In Arm B, 2 of 4 pts report a decrease in the number of A/M at wk 12. Mean norm-based wk 12 SF-36v2 bodily pain domain scores worsened by 4.1 in Arm A; an improvement of 1.9 in mean scores was observed in Arm B. Conclusions: Interim results show that a structured exercise program is well tolerated and compliance is high among women with aA related MSK symptoms. Early results point to a positive impact of exercise on MSK symptoms in women with early BC. Updated data will be presented. [Table: see text]
Collapse
Affiliation(s)
- R. J. Macfarlane
- BC Cancer Agency, Vancouver, BC, Canada; BC Cancer Agency, Victoria, BC, Canada
| | - C. Lohrisch
- BC Cancer Agency, Vancouver, BC, Canada; BC Cancer Agency, Victoria, BC, Canada
| | - P. Truong
- BC Cancer Agency, Vancouver, BC, Canada; BC Cancer Agency, Victoria, BC, Canada
| | - D. McKenzie
- BC Cancer Agency, Vancouver, BC, Canada; BC Cancer Agency, Victoria, BC, Canada
| | - D. Jespersen
- BC Cancer Agency, Vancouver, BC, Canada; BC Cancer Agency, Victoria, BC, Canada
| | - S. Nuraney
- BC Cancer Agency, Vancouver, BC, Canada; BC Cancer Agency, Victoria, BC, Canada
| | - K. Gaul
- BC Cancer Agency, Vancouver, BC, Canada; BC Cancer Agency, Victoria, BC, Canada
| | - K. Gelmon
- BC Cancer Agency, Vancouver, BC, Canada; BC Cancer Agency, Victoria, BC, Canada
| | - H. Kennecke
- BC Cancer Agency, Vancouver, BC, Canada; BC Cancer Agency, Victoria, BC, Canada
| |
Collapse
|
46
|
Chia SK, Lohrisch C, Gelmon K, Kennecke H, Pansegrau G, Taylor M, Attwell A, Jepson D, Hayes M, Shenkier T. Phase II trial of neoadjuvant sequential FEC100 followed by docetaxel and capecitabine for HER2-negative locally advanced breast cancer (LABC): A multicenter study from British Columbia. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.598] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
598 Background: Anthracyclines and taxanes are now standard of care for LABC. Phase III trials have demonstrated pathological complete responses of the breast (pCR) of 20–34% in studies of primary operable and LABC. Recent trials in the HER-2 negative population reported pCR rates of 20–29%.We have completed a multi-centre phase II trial of a neoadjuvant sequential anthracycline and taxane combination regimen in a HER-2 negative LABC population. Methods: Women with HER-2 negative stage IIB-IIIC breast cancer were enrolled. Treatment consisted of 4 cycles of FEC100 (5-FU 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2) followed by 4 cycles of XT (docetaxel 75 mg/m2 and capecitabine 1,000 mg/m2 PO BID x 14 days q3 weekly). Hormone receptor positive cases were prescribed standard endocrine therapy. A correlative translational component with baseline and interval biopsies and serum collection was also performed. Results: A total of 51 patients (27% stage IIB; 43% IIIA; 20% IIIB; and 10% IIIC) were accrued across 4 BCCA centres from November 2004-December 2007. Median age was 54 years (33–67 years). 59% of tumours were ER positive. There were no primary progressors on FEC100, though 2 patients had significant toxicities requiring early discontinuation. 3 patients (6%) developed clinical progression on XT. The majority of patients (79%) on XT required a dose reduction or delay. There were 5 episodes (10%) of febrile neutropenia. 15 patients (29%) underwent adjuvant radiotherapy prior to surgery. The pCR rate (breast and axilla) for the entire study population was 22% (11/51). In the ER+ and triple negative subtypes the pCR (breast and axilla) was 13% and 42%, respectively. Conclusions: This multi-centre phase II trial demonstrates activity for neoadjuvant anthracyclines followed by combination docetaxel/capecitabine in a HER-2 negative LABC population. Though the pCR rate was greater in the triple negative cohort, significant improvements are still required across the biological subtypes in HER-2 negative LABC. [Table: see text]
Collapse
Affiliation(s)
- S. K. Chia
- BC Cancer Agency, Vancouver, BC, Canada; BC Cancer Agency, Surrey, BC, Canada; BC Cancer Agency, Kelowna, BC, Canada; BC Cancer Agency, Victoria, BC, Canada
| | - C. Lohrisch
- BC Cancer Agency, Vancouver, BC, Canada; BC Cancer Agency, Surrey, BC, Canada; BC Cancer Agency, Kelowna, BC, Canada; BC Cancer Agency, Victoria, BC, Canada
| | - K. Gelmon
- BC Cancer Agency, Vancouver, BC, Canada; BC Cancer Agency, Surrey, BC, Canada; BC Cancer Agency, Kelowna, BC, Canada; BC Cancer Agency, Victoria, BC, Canada
| | - H. Kennecke
- BC Cancer Agency, Vancouver, BC, Canada; BC Cancer Agency, Surrey, BC, Canada; BC Cancer Agency, Kelowna, BC, Canada; BC Cancer Agency, Victoria, BC, Canada
| | - G. Pansegrau
- BC Cancer Agency, Vancouver, BC, Canada; BC Cancer Agency, Surrey, BC, Canada; BC Cancer Agency, Kelowna, BC, Canada; BC Cancer Agency, Victoria, BC, Canada
| | - M. Taylor
- BC Cancer Agency, Vancouver, BC, Canada; BC Cancer Agency, Surrey, BC, Canada; BC Cancer Agency, Kelowna, BC, Canada; BC Cancer Agency, Victoria, BC, Canada
| | - A. Attwell
- BC Cancer Agency, Vancouver, BC, Canada; BC Cancer Agency, Surrey, BC, Canada; BC Cancer Agency, Kelowna, BC, Canada; BC Cancer Agency, Victoria, BC, Canada
| | - D. Jepson
- BC Cancer Agency, Vancouver, BC, Canada; BC Cancer Agency, Surrey, BC, Canada; BC Cancer Agency, Kelowna, BC, Canada; BC Cancer Agency, Victoria, BC, Canada
| | - M. Hayes
- BC Cancer Agency, Vancouver, BC, Canada; BC Cancer Agency, Surrey, BC, Canada; BC Cancer Agency, Kelowna, BC, Canada; BC Cancer Agency, Victoria, BC, Canada
| | - T. Shenkier
- BC Cancer Agency, Vancouver, BC, Canada; BC Cancer Agency, Surrey, BC, Canada; BC Cancer Agency, Kelowna, BC, Canada; BC Cancer Agency, Victoria, BC, Canada
| |
Collapse
|
47
|
Cortés J, Baselga J, Petrella T, Gelmon K, Fumoleau P, Verma S, Pivot X, Ross G, Szado T, Gianni L. Pertuzumab monotherapy following trastuzumab-based treatment: Activity and tolerability in patients with advanced HER2- positive breast cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.1022] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1022 Background: Pertuzumab binds to the dimerization epitope of the HER2 receptor, inhibits HER dimerization and signal transduction, and induces ADCC. In 2 cohorts of pts (n = 66) with HER2-positive metastatic breast cancer which had progressed during trastuzumab therapy after ≤3 lines of chemotherapy with or without trastuzumab, pertuzumab plus trastuzumab has been shown to be active (CR 7.6%, PR 16.7%, SD ≥6/12 25.8%) (Gelmon et al. ASCO 2008, Abs 1026). To assess the activity of pertuzumab monotherapy in this clinical setting, the protocol was amended to include a 3rd cohort of pts. Methods: Pt selection was not changed except that ≥1 month between the last dose of trastuzumab and study start was required. Pts received pertuzumab monotherapy. If the tumor failed to respond or responded and then progressed, trastuzumab could be added to pertuzumab. 27 pts were to be recruited to ensure that ≥24 were fully evaluable for objective response and stabilization of disease ≥6 months. Standard 21-day schedules of the antibodies were given. Results: 29 pts were recruited. Tolerability was good: the major adverse events were mild diarrhea and rash with no clinical cardiac events. To date, 2 responses have been reported, and several pts have ongoing stabilization of disease. 14 pts have received trastuzumab plus pertuzumab following inadequate response (or response then relapse) on pertuzumab monotherapy. Of these 14, 2, having progressed during trastuzumab, failed to respond to pertuzumab monotherapy but underwent confirmed response when trastuzumab was added to the pertuzumab –possibly the first report of such a phenomenon and providing good evidence of an enhanced effect when the antibodies are combined. Updated results will be presented. Conclusions: Pertuzumab monotherapy is active against HER2-positive breast cancer which has progressed during trastuzumab-based therapy. The combination of the two antibodies appears to be more active than either antibody alone. The combination is also active in patients that had failed both antibodies given separately. In clinical studies, the use of the two antibodies combined is justified. [Table: see text]
Collapse
Affiliation(s)
- J. Cortés
- Vall d'Hebron University Hospital, Barcelona, Spain; Toronto-Sunnybrook Cancer Centre, Toronto, ON, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada; Centre Georges-François-Leclerc, Dijon, France; Ottawa Regional Cancer Center, Ottawa, ON, Canada; CHU Jean Minjoz, Besançon, France; Roche Products Limited, Welwyn, United Kingdom; Roche Products Limited, Welwyn, United Kingdom; Oncologia Medica, Milan, Italy
| | - J. Baselga
- Vall d'Hebron University Hospital, Barcelona, Spain; Toronto-Sunnybrook Cancer Centre, Toronto, ON, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada; Centre Georges-François-Leclerc, Dijon, France; Ottawa Regional Cancer Center, Ottawa, ON, Canada; CHU Jean Minjoz, Besançon, France; Roche Products Limited, Welwyn, United Kingdom; Roche Products Limited, Welwyn, United Kingdom; Oncologia Medica, Milan, Italy
| | - T. Petrella
- Vall d'Hebron University Hospital, Barcelona, Spain; Toronto-Sunnybrook Cancer Centre, Toronto, ON, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada; Centre Georges-François-Leclerc, Dijon, France; Ottawa Regional Cancer Center, Ottawa, ON, Canada; CHU Jean Minjoz, Besançon, France; Roche Products Limited, Welwyn, United Kingdom; Roche Products Limited, Welwyn, United Kingdom; Oncologia Medica, Milan, Italy
| | - K. Gelmon
- Vall d'Hebron University Hospital, Barcelona, Spain; Toronto-Sunnybrook Cancer Centre, Toronto, ON, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada; Centre Georges-François-Leclerc, Dijon, France; Ottawa Regional Cancer Center, Ottawa, ON, Canada; CHU Jean Minjoz, Besançon, France; Roche Products Limited, Welwyn, United Kingdom; Roche Products Limited, Welwyn, United Kingdom; Oncologia Medica, Milan, Italy
| | - P. Fumoleau
- Vall d'Hebron University Hospital, Barcelona, Spain; Toronto-Sunnybrook Cancer Centre, Toronto, ON, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada; Centre Georges-François-Leclerc, Dijon, France; Ottawa Regional Cancer Center, Ottawa, ON, Canada; CHU Jean Minjoz, Besançon, France; Roche Products Limited, Welwyn, United Kingdom; Roche Products Limited, Welwyn, United Kingdom; Oncologia Medica, Milan, Italy
| | - S. Verma
- Vall d'Hebron University Hospital, Barcelona, Spain; Toronto-Sunnybrook Cancer Centre, Toronto, ON, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada; Centre Georges-François-Leclerc, Dijon, France; Ottawa Regional Cancer Center, Ottawa, ON, Canada; CHU Jean Minjoz, Besançon, France; Roche Products Limited, Welwyn, United Kingdom; Roche Products Limited, Welwyn, United Kingdom; Oncologia Medica, Milan, Italy
| | - X. Pivot
- Vall d'Hebron University Hospital, Barcelona, Spain; Toronto-Sunnybrook Cancer Centre, Toronto, ON, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada; Centre Georges-François-Leclerc, Dijon, France; Ottawa Regional Cancer Center, Ottawa, ON, Canada; CHU Jean Minjoz, Besançon, France; Roche Products Limited, Welwyn, United Kingdom; Roche Products Limited, Welwyn, United Kingdom; Oncologia Medica, Milan, Italy
| | - G. Ross
- Vall d'Hebron University Hospital, Barcelona, Spain; Toronto-Sunnybrook Cancer Centre, Toronto, ON, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada; Centre Georges-François-Leclerc, Dijon, France; Ottawa Regional Cancer Center, Ottawa, ON, Canada; CHU Jean Minjoz, Besançon, France; Roche Products Limited, Welwyn, United Kingdom; Roche Products Limited, Welwyn, United Kingdom; Oncologia Medica, Milan, Italy
| | - T. Szado
- Vall d'Hebron University Hospital, Barcelona, Spain; Toronto-Sunnybrook Cancer Centre, Toronto, ON, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada; Centre Georges-François-Leclerc, Dijon, France; Ottawa Regional Cancer Center, Ottawa, ON, Canada; CHU Jean Minjoz, Besançon, France; Roche Products Limited, Welwyn, United Kingdom; Roche Products Limited, Welwyn, United Kingdom; Oncologia Medica, Milan, Italy
| | - L. Gianni
- Vall d'Hebron University Hospital, Barcelona, Spain; Toronto-Sunnybrook Cancer Centre, Toronto, ON, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada; Centre Georges-François-Leclerc, Dijon, France; Ottawa Regional Cancer Center, Ottawa, ON, Canada; CHU Jean Minjoz, Besançon, France; Roche Products Limited, Welwyn, United Kingdom; Roche Products Limited, Welwyn, United Kingdom; Oncologia Medica, Milan, Italy
| |
Collapse
|
48
|
Chia S, Bryce C, Pansegrau G, Macpherson N, Ellard S, Jepson D, Yu C, Nuraney S, Attwell A, Hayes M, Kennecke H, Gelmon K. Phase II trial of neoadjuvant chemotherapy of sequential FEC100 followed by docetaxel, carboplatin and trastuzumab (TCH) for HER-2 over-expressing locally advanced breast cancer (LABC): a multi-centre study from British Columbia. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-5118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #5118
Background: The role of trastuzumab either concurrent or sequential with adjuvant chemotherapy have clearly demonstrated significant benefits in early stage HER-2 positive breast cancer. There is now an accumulation of phase II and III trials also demonstrating improved pathological complete responses (pCR) in HER-2 positive breast cancer with neoadjuvant trastuzumab concurrent with chemotherapy. The number of patients on these trials are significantly fewer, and many of these trials are a mixture of primary operable and LABC. We have completed a multi-centre phase II trial of neoadjuvant chemotherapy and trastuzumab in HER-2 positive LABC.
 Methods: Women with HER-2 positive (IHC 3+ or FISH+) stage IIB-IIIC breast cancer were enrolled. Treatment consisted of 4 cycles of FEC100 (5-FU 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2) followed by 4 cycles of TCH (Docetaxel 75 mg/m2, carboplatin AUC 6, trastuzumab 8 mg/kg loading then 6 mg/kg q3 weekly). Trastuzumab was also continued adjuvantly for 9 months following chemotherapy and surgery. Cardiac monitoring every 3 months was mandated. A correlative translational component with baseline and interval biopsies and serum collection was also performed.
 Results: A total of 30 patients (3 stage IIB; 14 IIIA; 10 IIIB and 3 IIIC) over a 3 year time period in 4 centres were accrued. Median age was 49 years (26-77 years). 60% of tumours were ER negative. There was one clinical CHF and 2 asymptomatic falls in LVEF requiring early discontinuation of trastuzumab. There were 3 episodes (10%) of febrile neutropenia. Seven patients underwent adjuvant radiotherapy prior to surgery. The pCR rate (breast and axilla) for the entire study population was 60% (18/30). There have been 3 recurrences so far (all biopsy proven) – of which 2 were brain metastases only. Further details on toxicity and changes in LVEF will be presented.
 Conclusions: This multi-centre phase II trial clearly demonstrates significant activity (pCR 60%) for neoadjuvant anthracyclines followed by concurrent taxane, platinum and trastuzumab in a HER-2 positive LABC population. Overall the treatment regimen was well tolerated. Brain metastases however appear to be a common site of relapse in this high risk patient population and further treatment strategies directed at this site should be investigated.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 5118.
Collapse
Affiliation(s)
- S Chia
- 1 Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada
| | - C Bryce
- 1 Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada
| | - G Pansegrau
- 2 Medical Oncology, British Columbia Cancer Agency, Surrey, BC, Canada
| | - N Macpherson
- 3 Medical Oncology, British Columbia, Victoria, BC, Canada
| | - S Ellard
- 4 Medical Oncology, British Columbia, Kelowna, BC, Canada
| | - D Jepson
- 1 Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada
| | - C Yu
- 1 Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada
| | - S Nuraney
- 1 Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada
| | - A Attwell
- 3 Medical Oncology, British Columbia, Victoria, BC, Canada
| | - M Hayes
- 5 Pathology, British Columbia Cancer Agency, Vancouver, BC, Canada
| | - H Kennecke
- 1 Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada
| | - K Gelmon
- 1 Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada
| |
Collapse
|
49
|
Yerushalmi R, Gilks B, Nielsen T, Leang S, Cheang M, Woods R, Gelmon K, Kennecke H. Insulin like growth factor in breast cancer subtypes. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-3048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #3048
Background: Insulin Like Growth Factor -1 Receptor (IGF-1R) is an important new therapeutic target expressed in all cancer types. IGF-1R supports cell survival pathways implicated in resistance to cancer therapy. Knowledge of the pattern of IGF-R1 expression among breast cancer subtypes and its impact on prognosis may enhance development of therapeutics targeting this pathway.
 Methods: Patients with early breast cancer cases, stage I-III, referred to the BC Cancer Agency from 1986 to 1992 were included. Archival paraffin tissue blocks were used to construct a tissue microarray. Among 4,046 patients with early stage on the TMA, 1,238 patients (30.6 %) were excluded due to missing subtype biomarkers, IGFR staining or both. Breast cancer subtypes were defined as Luminal A (ER/PR+, HER2- and Ki67 <19%), Luminal B (ER/PR+,and HER2- and Ki67 >19%), Luminal HER2+ (HER2+ and ER/PR+), HER2 (HER2+ and ER-and PR-), and Basal {HER2-,ER-PR- and (CK 5/6+ and/or EGFR+)}. IGF-1R staining was done with Santa Cruz antibody and was scored negative if there was no or weak staining and positive if staining was moderate or strong. Chi-square and Kaplan-Meier Survival analysis were done to compare IGF-1R expression among subtypes and determine impact on Breast Cancer Specific (BCSS) and Overall Survival (OS).
 Results: A total of 2,808 evaluable cases were included with a median follow-up of 12.5 years. IGF-1R staining was scored positive in 86.4%, and negative in 13.6%. Cases with Luminal A (1,676), Luminal B (426), Luminal HER2+ (199), HER2 (206 ) and Basal (301 ) had an IGF-1R+ rate of 89.9%, 94.4 %, 83.4%, 59.2% and 76.1%, respectively (p<0.0001). 10 year BCSS was 68% (95% CI 66.0%-70.0%) in IGF-R1+ and 63% (95% CI 59.1%-66.9%) in IGF-R1 - group. Among subtypes, IGF-1R positivity was associated with improved BCSS only in Luminal A patients (p=0.015 ) and was not prognostic in other subtypes.
 Conclusion: Luminal breast cancer subtypes are associated with high rates of IGF1-R expression, while non-luminal groups have lower rates of expression. The prognostic impact of IGF-R1 expression supports the role of this pathway as a therapeutic target particularly among hormone receptor positive breast cancer.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 3048.
Collapse
Affiliation(s)
- R Yerushalmi
- 1 Division of Medical Onclogy, BC Cancer Agency, Vancouver, BC, Canada
| | - B Gilks
- 2 Genetic Pathology Evaluation Center, Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada
| | - T Nielsen
- 2 Genetic Pathology Evaluation Center, Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada
| | - S Leang
- 1 Division of Medical Onclogy, BC Cancer Agency, Vancouver, BC, Canada
| | - M Cheang
- 2 Genetic Pathology Evaluation Center, Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada
| | - R Woods
- 1 Division of Medical Onclogy, BC Cancer Agency, Vancouver, BC, Canada
| | - K Gelmon
- 1 Division of Medical Onclogy, BC Cancer Agency, Vancouver, BC, Canada
| | - H Kennecke
- 1 Division of Medical Onclogy, BC Cancer Agency, Vancouver, BC, Canada
| |
Collapse
|
50
|
Kennecke HF, Yerushalmi R, Woods R, Cheang M, Voduc D, Speers C, Nielsen T, Gelmon K. The pattern of metastatic spread among breast cancer sub-types. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-2025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #2025
Background: Although breast cancer subtypes are associated with differing relapse risks, the patterns of metastatic spread are less well defined, particularly for more than the first site of metastasis. We describe the sites of all diagnosed metastases among breast cancer subtypes in a large series of women diagnosed with breast cancer to further define patterns of spread.
 Methods: Subjects with early stage breast cancer referred to the British Columbia Cancer Agency from 1986 to 1992 were included. Archival paraffin tissue blocks were used to construct a tissue microarray. Breast cancer subtypes were defined as Luminal A (ER/PR+ and HER2- and Ki67 <19%), Luminal B (ER/PR+, and HER2- and Ki67 >19%), LuminalHer2 (Her2+ and ER/PR+), HER2 (HER2+ and ER- and PR-), and Basal (HER2-ER-PR- and CK 5/6+and/orEGFR+). All documented sites of distant metastasis were abstracted by chart review according to predefined categories.
 Results: 3526 eligible women were classified according to Luminal A (2109), Luminal B (514), LuminalHER2 (252), HER2 (276) and Basal (375) and 30%,47%, 48%, 50% and 42% in each subgroup were diagnosed with distant metastasis. Median Survival with metastatic disease was 2.2, 1.6 and 1.3 years in Luminal A, B and LuminalHER2 groups and 0.7 and 0.5 years in the HER2 and Basal types, respectively. Bone was the predominant site of metastasis for luminal groups A (76%), B (73%) and LuminalHER2 (70%). The distribution was more heterogeneous in HER and Basal groups. High rates of brain metastasis were observed in the HER2 (30%) and Basal (27%) and less frequently in the LuminalHER2 (17%) and other groups (p <0001).
 
 Conclusion: Molecular breast cancer subtypes are associated with specific distributions of metastasis which may lead to specific prophylactic therapies to modify this risk. New systemic therapies, including trastuzumab, may impact these patterns and survival after recurrence.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 2025.
Collapse
Affiliation(s)
- HF Kennecke
- 1 British Columbia Cancer Agency, Vancouver, BC, Canada
| | - R Yerushalmi
- 1 British Columbia Cancer Agency, Vancouver, BC, Canada
| | - R Woods
- 1 British Columbia Cancer Agency, Vancouver, BC, Canada
| | - M Cheang
- 1 British Columbia Cancer Agency, Vancouver, BC, Canada
| | - D Voduc
- 1 British Columbia Cancer Agency, Vancouver, BC, Canada
| | - C Speers
- 1 British Columbia Cancer Agency, Vancouver, BC, Canada
| | - T Nielsen
- 1 British Columbia Cancer Agency, Vancouver, BC, Canada
| | - K Gelmon
- 1 British Columbia Cancer Agency, Vancouver, BC, Canada
| |
Collapse
|